KAPL Search   GO

Corporate Info
Manufacturing Facilities
Domestic Marketing
International Marketing
Company News
Doctor's Section
Products Ready Recknor
Feedback
Enquiries
Current Job Openings
Grievance Cell - Department of Pharmaceuticals
Application form for employment
Vigilance
Tenders
RTI
Back Home


DOCTOR'S SECTION  » Therapeutic Index

AG-X ™

The first line anti-bacterial anti-septic

D E S C R I P T I O N / M O D E O F A C T I O N

AG-X cream is a combination of Chlorhexidine gluconate and Silver sulfadiazine, specially suitable for cuts, burns, wounds and bruises. Silver sulfadiazine is known to exert a powerful broad spectrum antibacterial property and is used traditionally in modern medicine. Chlorhexidine is known to exhibit the antiseptic properties effective against a wide range of bacteria, fungi and some viruses. In combination, two together exert a potent anti-infective anti-septic and antimicrobial action against various skin infecting organisms. Both Silver sulfadiazine and Chlorhexidine have bactericidal action. Silver sulfadiazine inactivates Varicella Zoster virus and is useful as 1% cream. Definite clinical response have been observed in indications like Herpes Zoster.

C O M P O S I T I O N

Each AG-X cream contains :
Silver sulfadiaine 1% w/w
Chlorhexadine gluconate 0.20% w/w
Cream base q.s.

I N D I C AT I O N S

Day to day skin injuries like cuts, burns, wounds and bruises. AG-X can be used for the prevention and treatment of leg ulcers, prevention of skin infection after skin grafting and in the treatment of Herpes Zoster infection.

D O S A G E

To be topically applied on the affected areas 2-3 times a day.

S I D E E F F E C T S

Widespread extensive application may lead to systemic absorption. In rare cases there could be transient leucopenia. Possibility of Argyria can not be ruled out, though the same is very rare in occurrence. AG-X is contraindicated in hypersensitivity to either Chlorhexidine or Silver sulfadiazine.

P R E S E N TAT I O N & PACK

Tubes of 10 gm & 100 gm packed in a carton.

Alerbloc™

The most trusted antihistaminic

D E S C R I P T I O N / M O D E O F A C T I O N
Alerbloc is a piperazine derivative with a carboxyl group on the side chain. The carboxyl is ionised at physiological pH and carries a negative charge resulting in a higher polar compound with poor ability to cross the blood-brain barrier. Cetrizine is a potent, non-sedating, second generation antihistamine with a high specificity for H1 receptors. In addition, it reduces migration of inflammatory cells and therefore inhibits cutaneous late response. Cetrizine has a rapid onset and a long duration of action. It has no significant effects at the muscarinic and serotoninergic receptors. Cetirizine is absorbed rapidly and almost completely after oral administration. Peak plasma levels of 257 and 580 mcg/L are reached within one hour of oral doses of 10 and 20 mg respectively. First pass effect is insignificant. Binding to plasma proteins is 93%. The major route of elimination is the kidney. About 60% of the dose is eliminated in the urine within 24 hours in an unchanged form. A further 10% is eliminated in the urine over the next 4 days, The mean elimination half-life of cetirizine is 7.4 h.

C O M P O S I T I O N

Each tablet contains : Cetirizine HCl 10 mg
Each 5 ml syrup contains : Cetirizine HCl 5 mg

I N D I C AT I O N S

Cetirizine hydrochloride is indicated for the treatment of the following conditions :
vSeasonal allergic rhinitis
vPerennial allergic rhinitis
vChronic idiopathic urticaria
v Allergic conjunctivitis
v Atopic dermatitis
v Infantile eczema
v Prutritis
v As an adjunct in asthma management

D O S A G E

Adults : Usual dosage is 10 mg once a day. If necessary the dose may be increased up to 10 mg twice a day.
Children : 6 years and over : 5 to 10 mg once a day.
Below 6 years : There are no clear data about the use of Cetirizine in children below 6 years.
However, a dose of 5 mg once daily or 2.5 mg BID has been suggested for children 2-5 years old.
Elderly patients do not require any dose adjustments unless renal impairment is present.
In patients with renal impairment : 5 mg once daily.

S I D E E F F E C T S

Cetirizine is generally well tolerated. Side effects reported from placebo-controlled studies include headache, dry mouth, fatigue and nausea or vomiting. Sedation produced by cetirizine was not greater than with Placebo, Astermizole, Loratidine or Terfenadine, but was considerably less than with Ketotifen, Pheniramine or Chlorpheniramine. Cetirizine 20 or 60 mg / day for 7 days did not prolong Q T interval in the ECG of 20 healthy volunteers. There have been no reports of arrhythmia or cardiac abnormalities.

P R E S E N TAT I O N & PACK

Strips of 10 x 10’s tablet in blister pack
Syrup of 60 ml bottle

Antaf ™

An ulcer healing and antiflatulent agent

S C R I P T I O N / M O D E O F A C T I O N
Antaf is an excellent ayurvedic antiulcer and antiflatulent agent. Antaf neutralises acid and over comes flatulence. Antaf heals gastric and duodenal ulcer. It gives relief from abdominal discomfort and epigastric pain. Provides immediate relief from heart burn, sour erructations, constipation, nausea and vomiting. Action of Antaf is sustained.

C O M P O S I T I O N

Each tablet contains extracts equivalent to :
Qty. in mg
Glycyrrhiza glabra (Yashtimadhu) 150
Embelica officinalis (Amalaki) 150
Narikela lavana 100
Shankha bhasma 100

I N D I C AT I O N S

Antaf is indicated in hyperacidity, gastric and duodenal ulcer.

D O S A G E

2 tablets tid or as directed by the physician

S I D E E F F E C T S

Being an ayurvedic preparation, no untoward side effects are noticed.

P R E S E N TAT I O N & PACK

Container of 30’s tablet


CEFPAR™ & CEFPAR - SB™

THE PROVEN POWER OF ANTIMICROBIAL AGENT / SYNERGY

D E S C R I P T I O N / M O D E O F A C T I O N

CEFPAR is only Cefoperazone sodium whereas CERPAR – SB is a combination of Cefoperazone sodium and Sulbactam sodium (1:1). Both exhibit a broad spectrum of antimicrobial activity on Gram negative, Gram positive and Anaerobic organisms. They are very much useful in emergency cases where other antibiotics are found ineffective because of their high degree of reliability with wider spectrum of activity. Cefpar – SB exhibits antimicrobial synergy and has lower MIC than Cefoperazone alone. Also Sublactam enhances the antibacterial potency of Cefoperazone in Cefpar - SB.

C O M P O S I T I O N

CEFPAR : Each vial (dry powder for injection) contains – Cefoperazone sodium USP 500mg / 1g.
CEFPAR - SB : Each vial (dry powder for injection) contains – Cefoperazone sodium USP 500mg / 1g.
Sulbactam sodium USP 500mg / 1g.

I N D I C AT I O N S

Monotherapy : They are indicated for the treatment of the following infections when caused by susceptible organisms – Respiratory tract infections (Upper and Lower), Urinary tract infections (Upper and Lower), Peritonitis, Cholecystitis, Cholangitis, and other Intra abdominal infections, Septicemia, Meningitis, Pelvic inflammatory disease, Endometritis, Gonorrhea and other infections of the Genital tract, Skin and soft tissue infections, Bone and joint infections.
Combination therapy : Because of the broad spectrum of activity of Cefpar – SB, most infections cn be treated adequately with this alone. However, it may be used concomtantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used, renal function shoud be monitored during the course of therapy.

D O S A G E

Cefpar: 1g or 2g every 12 hours in adults and 50 to 200mg / kg daily in children. For neonates aged less than 8 days, the drug shoud not be given more frequently than 12 hourly. The daily dose may be increased to 8g or 300 mg/kg/day in severe infections.
Cefpar – SB: 2g to 4g every 12 hours in adults 40 to 80mg / kg daily in children every 6 to 12 hours in equally divided doses. The recommended maximum daily dosage of sulbactam is 4g. For neonates in the first week of life, the drug should be given every 12 hours. The maximum daily dosage of sulbasctam in paediatrics should not exceed 80mg/kg/day. If more than 80mg/kg/day of cefoperazone activity are necessary, additional cefoperazone should be administered seperately.

S I D E E F F E C T S

Contraindications: Known hypersensitivity to cephalosporin class of antibiotics.
Warning: Both CEFPAR & CEFPAR – SB should be administered with caution to any patient who is penicillin sensitive or has demonstrated any other form of allergy, particularly to drugs.
The adverse reactions include allergic reactions, reversible neutropenia, positive direct Coomb’s test, anemia and reduced hematocrit, transient eosinophilia and hypoprothrombinemia have been reported. Transient elevation of SGOT, SGPT, and alkaline phosphatase may occur. Loose stools or diarrhea of mild to moderate severity may occur and is reversible when therapy is terminated. Phlebitis at the site of infusion or transient pain on intramuscular administration may occur in some patients.

P R E S E N TAT I O N & PACK

CEFPAR 500mg / 1g & CEFPAR – SB (1:1) 1g / 2g are presented in vials with unit pack.
CEFPAR – SB (1:1) 1g / 2g are presented in vials with unit pack.


Cetriax™

A high profile once a day criticare injectable antibiotic

D E S C R I P T I O N / M O D E O F A C T I O N
Cetriax is a 3rd generation Cephalosporin with broad spectrum antimicrobial activity. Cetriax cannot be given orally. Usually given intravenously or intramuscularly. It covers most of the gram positive and gram negative organisms. It is highly resistant to betalactamases, including penicillinase and cephalosporinases produced by gram negative and gram positive organisms. Cetriax has 24 hours anti-microbial action by inhibiting cell wall synthesis by breaking down peptidoglycon ring. Plasma concentration achieved by Cetriax is more than MIC required. MIC is less than 8 mcg / ml for most organisms. Peak plasma concentrations are reached within 30 minutes. Cetriax is widely distributed in various tissues and body fluids. High levels are detected in respiratory tract, bone and joints, urinary tract, skin and abdominal organs. It readily enters CSF especially across inflamed meninges. Cetriax also penetrates into vitreous humour. Cetriax crosses the placenta and is excreted in breast milk. Cetriax is not metabolised in the body and has dual excretion by kidneys and rest is secreted into the bile and excreted in the feaces. Plasma protein binding averages between 85 - 95%. Elimination half life is 5.8 - 8.7 hours. Cetriax has the longest half-life among Cephalosporins.

C O M P O S I T I O N
Each vial of Cetriax contains : 250 mg or 1 gm of Sterile Ceftriaxone sodium.

I N D I C AT I O N S
Cetriax is reccommended in :
Bacterial meningitis, Bacterial septicemia,
Surgical prophylaxis, Sexually transmitted diseases,
Respiratory tract infections, Urinary tract infections,
Serious skin and soft tissue infections, Pelvic inflammatory diseases,
Infective endocarditis & Osteomyelitis.

D O S A G E
Adults : The usual dose is 1 to 2 gm given once a day or in 2 eqully divided doses twice a day depending on the type and severity of infection. The total daily dose should not exceed 4 gm. For uncomplicated gonorrhoea, a single IM dose of 250mg is given. For surgical prophylaxis, the recommended dose is 1gm given 1/2 to 2 hours before surgery.
Children : Skin and soft tissue infections, 50 – 75 mg / kg / day given once a day or in 2 equally divided doses in a day. The total dose should not exceed 2 gm. For serious infections other than meningitis, the daily dose is 50 to 75 mg / kg in divided doses every 12 hours. Total daily dose should not be more than 2 gm. For meningitis a daily dose of 100 mg / kg limited to a maximum of 4 gm / day is given in divided doses every 12 hours. No dose modification is needed in patients with renal or hepatic impairment. Cetriax should be continued for at least 3 days after the patient becomes asymptomatic. The usual duration of treatment is at least for 10 days.

S I D E E F F E C T S
Cetriax is generally well tolerated. Rarely it can produce local reactions, like pain, induration and phlebitis, hypersensitivity reactions like rash, pruritus and fever, eversible biliary pseudolithiasis, super infection with candida, pseudomembranous colitis and vaginitis, Haematological abnormalities like eosinophilia, thrombocytosis, leucopenia and neutropenia. Cetriax should not be given to patients who are allergic to penicillins or cephalosporins. In patients with both hepatic and renal dysfunction the dose of Cetriax should not exceed 2 gms/day. In patients with impaired Vitamin K synthesis eg. Malnutrition, chronic liver disease etc., prothrombin time (PT) should be checked. Cetriax has to be given in pregnancy and nursing mothers only if it is very essential. Cetriax should not be given if there is hyperbilirubinaemia.

P R E S E N TAT I O N & PACK
Cetriax 1.0 gm - Vials containing Ceftriaxone Sodium 1 gm with 10 ml sterile water for injection, in a shock
proof tray packed in individual carton.
Cetriax 250mg - Vials containing Ceftriaxone Sodium 250 mg with 5 ml sterile water for injection, packed in a
separate carton.

Cetriax™ - S / S 375

A high profile once a day criticare injectable antibiotic

D E S C R I P T I O N / M O D E O F A C T I O N
Cetriax is a 3rd generation Cephalosporin with broad spectrum antimicrobial activity. Cetriax cannot be given orally. Usually given intravenously or intramuscularly. It covers most of the gram positive and gram negative organisms. It is highly resistant to betalactamases, including penicillinase and cephalosporinases produced by gram negative and gram positive organisms. Cetriax has 24 hours anti-microbial action by inhibiting cell wall synthesis by breaking down peptidoglycon ring. Plasma concentration achieved by Cetriax is more than MIC required. MIC is less than 8 mcg / ml for most organisms. Peak plasma concentrations are reached within 30 minutes. Cetriax is widely distributed in various tissues and body fluids. High levels are detected in respiratory tract, bone and joints, urinary tract, skin and abdominal organs. It readily enters CSF especially across inflamed meninges. Cetriax also penetrates into vitreous humour. Cetriax crosses the placenta and is excreted in breast milk. Cetriax is not metabolised in the body and has dual excretion by kidneys and rest is secreted into the bile and excreted in the feaces. Plasma protein binding averages between 85 - 95%. Elimination half life is 5.8 - 8.7 hours. Cetriax has the longest half-life among Cephalosporins.
Sulbactum – semisynthetic beta lactumase inhibitor, highly active against class II to IV beta lactamase. It has been combined with extended spectrum penicillins & cephalosporins for use against beta lactumase producing resistant strains.

C O M P O S I T I O N
Each vial of Cetriax – S contains : Sterile Ceftriaxone Sodium 1 gm + Sulbactam Sodium 500 mg.
Each vial of Cetriax – S 375 contains : Sterile Ceftriaxone Sodium 250 mg + Sulbactam Sodium 125 mg.

I N D I C AT I O N S
Cetriax is reccommended in :
Bacterial meningitis, Bacterial septicemia,
Surgical prophylaxis, Sexually transmitted diseases,
Respiratory tract infections, Urinary tract infections,
Serious skin and soft tissue infections, Pelvic inflammatory diseases,
Infective endocarditis & Osteomyelitis.

D O S A G E
Adults : The usual dose is 1 to 2 gm given once a day or in 2 eqully divided doses twice a day depending on the type and severity of infection. The total daily dose should not exceed 4 gm.
Children : Skin and soft tissue infections, 50 – 75 mg / kg / day given once a day or in 2 equally divided doses in a day. The total dose should not exceed 2 gm. For serious infections other than meningitis, the daily dose is 50 to 75 mg / kg in divided doses every 12 hours. Total daily dose should not be more than 2 gm. For meningitis a daily dose of 100 mg / kg limited to a maximum of 4 gm / day is given in divided doses every 12 hours. No dose modification is needed in patients with renal or hepatic impairment.
S I D E E F F E C T S
Cetriax is generally well tolerated. Rarely it can produce local reactions, like pain, induration and phlebitis, hypersensitivity reactions like rash, pruritus and fever, eversible biliary pseudolithiasis, super infection with candida, pseudomembranous colitis and vaginitis, Haematological abnormalities like eosinophilia, thrombocytosis, leucopenia and neutropenia. Cetriax should not be given to patients who are allergic to penicillins or cephalosporins. In patients with both hepatic and renal dysfunction the dose of Cetriax should not exceed 2 gms/day. In patients with impaired Vitamin K synthesis eg. Malnutrition, chronic liver disease etc., prothrombin time (PT) should be checked. Cetriax has to be given in pregnancy and nursing mothers only if it is very essential. Cetriax should not be given if there is hyperbilirubinaemia.

P R E S E N TAT I O N & PACK
Cetriax 1.0 gm - Vials containing Ceftriaxone Sodium 1 gm with 10 ml sterile water for injection, in a shock
proof tray packed in individual carton.
Cetriax 250mg - Vials containing Ceftriaxone Sodium 250 mg with 5 ml sterile water for injection, packed in a
separate carton.

Cidogrel™ & Cidogrel – A ™

THE JUST RIGHT ANTIPLATELET

D E S C R I P T I O N / M O D E O F A C T I O N

Cidogrel is only Clopidogrel bifulphate and Cidogrel – A is combination of Clopidogrel bisulphate and Aspirin. Clopidogrel is an inhibitor of platelet aggregation and as such is not effective. It can become effective only after hepatic metabolism by P450 – CYP enzyme. The activated metabolite blocks the P2 purinoceptors (purine receptors) located on the surface of platelets. It inhibits the ADP induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GP IIb / IIIa complex. This clopidogrel – sensitive purinoceptor is thought to be linked to adenylyl cyclase. Hence these receptors are also called as P2YAC receptors. Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral dose of clopidogrel. It is rapidly aborbed after oral administration and approxmately 50% was excreted in the urine and 46% in the faeces. The elimination half life of the main circulating metabolite was 8 hours with a half life of 11 days. Aspirin did not modify the clopidogrel – mediated inhibition of ADP induced platelet aggegation. Aspirn acts by inhibiting thromboxane A2 which inhibit platelet aggregation.


C O M P O S I T I O N

Cidogrel – Each film coated tablet contains : Clopidogrel bisulphate 75 mg.
Cidogrel – A : Each film coated tablet contains : Clopidogrel bisulphate 75 mg.
Aspirin IP 75 mg.

I N D I C AT I O N S

Cidogrel and Cidogrel – A are indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease. It is also indicated in the treatment of unstable angina.

D O S A G E

Cidogrel : Usually 1 tablet given once daily. A loading dose upto 4 tablets may be given in specific cases.
Cidogrel – A : Usually 1 tablet given once daily.

S I D E E F F E C T S

According to CAPRIE study the following were observed – Gastro intestinal : Abdominal pain, dysepsia, gastritis, and constipation. Haemorrhgic : GI haemorrhage, neutropenia / agranulocytosis. Rash & other skindisorders : Skin and appendage disorders. Others include – Syncope, palpitation, hernia, cardiac failure, vomiting, leg cramps, increased hepatic enzymes, anxiety, insomnia, anaemia, skin ulceration, decreased platelets,sinusitis, eczema.

P R E S E N TAT I O N & PACK

Cidogrel and Cidogrel – A are presented in Alu. Strips of 3 X 10’s tablets in carton.

Cyfolac™

The pro-biotic rejuvenator

D E S C R I P T I O N / M O D E O F A C T I O N

Cyfolac is a combination of Lactic acid bacillus, Folic acid and Vitamin B12. It is used as an excellent microbiotherapy adjuvant to antibiotic therapy. Lactic acid bacillus has both nutritive and therapeutic value. It restores normal intestinal flora.

C O M P O S I T I O N

Each capsule / DT of Cyfolac contains :
Lactic acid bacillus 120 million spores
Folic acid 1.5 mg
Vitamin B12 15 mcg

Cyfolic Jr. tab contains :
Lactic acid bacillus 60 million spores
Folic acid 1.5 mg
Vitamin B12 15 mcg


I N D I C AT I O N S

Cyfolac is indicated as an adjuvant with antibiotics and anti- diarrhoeals, in habitual constipation, dyspepsia, vomiting, flatulence, stomatitis, glossitis and gingivitis. It is an excellent supplement in infantile diarrhoea and gastrointestinal disorders in children.

D O S A G E

The recommended dosage : 10 million spores / kg body weight. Usually 1 capsule / tablet thrice daily.
Infants : 50 million spores 3 times a day.
Children: 50 to 100 million spores 3 times a day.
Adults : 100 to 200 million spores 3 times a day.

S I D E E F F E C T S

Cyfolac is generally well tolerated and hyper-sensitivity is rarely seen.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s caps in blister pack.
Strips of 10 X 10’s blister pack of Cyfolac DT / Jr.


Cyfolac™ Forte

A Fruitful Concept of Prebiotic & Probiotics

D E S C R I P T I O N / M O D E O F A C T I O N

Supplementing probiotics with prebiotics, which are agents that stimulate the growth and / or activity of nonpathogenic bacteria, is more beneficial than administering only probiotics. This combination of probiotics and prebiotics, called synbiotics, is gaining high interest and widespread use in the medical fraternity. Prebiotics may stimulate probiotic bacteria not only to grow, but also to produce compounds beneficial to the host. Their colonic fermentation produces short chain fatty acids [SCFAs] and lactic acid, which is important factors determining the pH of the colonic lumen.

C O M P O S I T I O N

Each Capsule contains : Each Sachet contains :

Lactobacillus acidophilus - 0.75 Billion Lactobacillus acidophilus - 0.4 Billion
Lactobacillus rhamnosus - 0.75 Billion Lactobacillus rhamnosus - 0.4 Billion
Bifidobacterium longum - 0.75 Billion Bifidobacterium longum - 0.4 Billion
Bifidobacterium bifidum - 0.75 Billion Bifidobacterium bifidum - 0.4 Billion
Saccharomyces boulardii - 0.1 Billion Saccharomyces boulardii - 0.05 Billion
Fructo Oligo saccharides - 100 mg Fructo Oligo saccharides - 100 mg

I N D I C AT I O N S

Clinical applications of probiotics in GI conditions
· Diarrhoeas of various origins
- Antibiotic associated diarrhoea
- Rotavirus diarrhoea
- Traveler’s diarrhoea
- Gastroenteritis
- Nosocomial diarrhoea
- Clostridium difficile diarrhoea
- HIV/AIDS diarrhoea
- Enteral feeding-associated diarrhoea
· Irritable bowel syndrome
· Inflammatory bowel disease
· Reduction of antibiotic-associated GI side effects
· Food allergies and lactose intolerance
· Colon cancer
· Pancreatitis
· H.pylori infection

D O S A G E

Dosage : The recommended dosage
Adults : 1 – 2 Caps per day
Children : 1 – 2 Sachets per day

S I D E E F F E C T S

Cyfolac Forte is generally well tolerated and hyper-sensitivity is rarely seen.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s caps in Alu - Alu pack.
Sachet of 5 gm pack.

Dycon™

An anti-diarrhoeal and anti-dysenteric agent

D E S C R I P T I O N / M O D E O F A C T I O N
Dycon is an ayurvedic antidiarrhoeal and antidysenteric with specific ingredients. Dycon stops diarrhoea and treats chronic dysentery. Dycon regulates the secretion of digestive system and helps to overcome irritable bowel syndrome. Dycon helps in relieving tenesmus and flatulence.

C O M P O S I T I O N
Each tablet / 5 ml syrup of Dycon contains, extracts equivalent to :

Qty. in mg / tab Qty. in mg / 5 ml

Holarrhena antidysentrica (Kutaja) 200 20
Myristica fragrans (Jatiphala) 10 10
Punica granatum (Dadima) 75 100
Aegle masrmelos (Bilva) 20 40
Zingiber officinale (Sringavera/Shunti) 5 5
Cuminum cyminum (Sweta jeeraka) 10 10

I N D I C AT I O N S

Dycon tablet / syrup are indicated in diarrhoea, dysentery, mixed infections.

D O S A G E

Syrup : 2.5 ml – 5 ml t.i.d.
Tablet : 2 tablets t.i.d.

P R E S E N TAT I O N & PACK

Syrup : Bottle of 100 ml.
Tablet : Container of 30’s.


Emidon™

A potent antiemetic tablet and suspension

D E S C R I P T I O N / M O D E O F A C T I O N
Emidon is a potent antiemetic, very useful in nausea and vomiting. Emidon is a dopamine antagonist acts centrally by inhibiting dopamine receptors at CTZ and peripherally acts on G.I. tract, by increasing LES pressure by enhancing gastric contractions and relaxing the pyloric sphincter pressure. Emidon DT is well absorbed orally and peak plasma level is achieved in 30 minutes. Emidon is rapidly distributed and does not cross B.B.B. It undergoes first pass metabolism, its bioavailability is 18% and half-life is 7 hours. Emidon is excreted 80% in faeces and 20% in urine.

C O M P O S I T I O N

Each tablet of Emidon DT contains Domperidone HCl 10 mg in dispersible form.
Suspension contains 5 mg per 5 ml of Domperidone HCl.

I N D I C AT I O N S

Emidon is indicated in diabetic gastroparesis, nausea and vomiting, acid regurgitation, reflex oesophagitis, heart burn, flatulent dyspepsia and as an adjuvant to H2 receptor antagonists in gastric ulcers.

D O S A G E

Adults : 10 mg to 20 mg orally once in 8 hours.
20 mg to 30 mg three times daily for diabetic gastroparesis.
Children : 0.2 mg to 0.4 mg / kg once in 8 hours

S I D E E F F E C T S

There are no known serious side effects with Emidon. However, peripheral dopaminergic side effects like dry mouth, diarrhoea and very rearely galactorrhoea and gynaecomastia have been observed. Though, safety in pregnancy has not yet been established, there were no teratogenic effects reported also. CNS side effects like dystonia and extra pyramidal syndromes are least likely as Emidon is not likely to cross B.B.B.

P R E S E N TAT I O N & PACK

Strips of 10x10’s dispersible tablets in blister pack
Suspension 30 ml pack

Emidon - OM™

THE GASTROKINETIC ANTIULCERANT

D E S C R I P T I O N / M O D E O F A C T I O N

Emidon – OM is the best and safest combination of dopaminergic antagonist Domperidone and the time tested proton pump inhibitor Omeprazole for proper reversal of GERD and Hyperacidity. It blocks oesophageal reflux by ensuring prompt prokinesis and increasing LES pressure. It also acts by inhibiting acid secretion and decreasing gastric emptying time.

C O M P O S I T I O N

Each capsule of Emidon – OM contains : Domperidone BP 10 mg.
Omeprazole IP 20 mg. (Enteric Coated Pellet)

I N D I C AT I O N S

Emidon – OM is indicated in Reflux oesophagitis, Peptic ulcer and Flatulent dyspepsia.

D O S A G E

The recommended dosage is one capsule before breakfast and one before evening meal.

S I D E E F F E C T S

There are no known serious side effects with Emidon - OM. However, peripheral dopaminergic side effects like dry mouth, diarrhoea and very rarely galactorrhoea and gynaecomastia have been observed. Though, safety in pregnancy has not yet been established, there were no teratogenic effects reported also. CNS side effects like dystonia and extra pyramidal syndromes are least likely as Emidon - OM is not likely to cross Blood Brain Barrier.

P R E S E N TAT I O N & PACK

Emidon – OM is presented in Alu. Strips of 10 X 6’s capsules in a carton.


EXOL™

A Hepatobiliary stimulant

D E S C R I P T I O N / M O D E O F A C T I O N

Exol is an ayurvedic hepatobiliary stimulant. Exol is a comprehensive formula with specific combination in the treatment of hepatic diseases. Exol promotes growth, improves appetite, digestion and ensures better absorption. Exol protects liver from hepatic damage, it helps elliminate hepatotoxins. Exol stimulates and increases the functional effeciency of liver enzymes. Exol promotes hepatocellular repair and regeneration and helps overcome alcohol toxicity on liver.

C O M P O S I T I O N

Each tablet / 5 ml syrup of Exol contains extract equivalent to :

Qty. in mg / tab Qty. in mg / 5 ml

Picrorhiza kurroa (Katuki) 40 20
Phyllanthus niruri (Bhoomyamalaki) 75 30
Tecomella undulata (Rohitaka) 50 20
Tephrosia purpurea (Shara punkha) 100 50
Eclipta alba (Bhringaraja) 80 50
Boerrhavia diffusa (Punarnava) 25 20
Azadirachta indica (Nimbea) 30 -

I N D I C AT I O N S

Exol is indicated in jaundice, infective hepatitis, cirrhosis of liver and digestive disorders.

D O S A G E

Syrup : Adults – 10 ml t.i.d
Children – 5 ml t.i.d
Tablet : – 2 tablet t.i.d or 2 tablet o.i.d as health supplement.

S I D E E F F E C T S

Being an ayurvedic preparation no untoward side effects are reported.

P R E S E N TAT I O N & PACK

Syrup – Bottle of 100 ml.
Tablets – Container of 100’s.

FACITAB™

Simple yet vital supplement in pregnancy care

D E S C R I P T I O N / M O D E O F A C T I O N

Facitab contains Folic acid or Pteroylglutamic acid (PteGlu); which is the common pharmaceutical form of folic acid. It is neither the principal folate congener in the food nor the active coenzyme for intracellular metabolism. Following absorption, PteGlu is rapidly converted to Tetrahydro folicacid (H4PteGlu).H4PteGlu is further converted to congeners like Tetrahydrofolate, Methenyl tetrahydrofolate, Methylene tetrahydrofolate, Formyl tetrahydrofolate. These congeners help in the synthesis of amino acids like Methionine, Glycine, Thymidylate, Purines, Formates. These amino acids act as enzymes to catalyze other reactions necessary for the survival and normal functions of cells including cell divisions.

C O M P O S I T I O N

Each tablet contains : Folic acid IP 5 mg

I N D I C AT I O N S

vDietary deficiency.
vAnaemia of pregnancy.
vMalabsorption syndromes.
vTropical sprue.
vGluten enteropathy.
vSteatorrhoea.
vChronic haemolytic states.
vAnticonvulsant therapy.
vNeural tube defects.

D O S A G E

Adults : 5 – 20 mg ( 1 – 4 tabs. ) daily.
Children: 5 – 10 mg ( 1 – 2 tabs. ) daily.

S I D E E F F E C T S

Allergic reaction can occur very rarely and only high doses of Folic acid may decrease the effectiveness of Phenobarbitone, Phenytoin and Primidone.

P R E S E N TAT I O N & PACK

Facitab is available in 10 X 10’s blister pack tablets.


Fubac ™

AN ANTI-FUNGAL & ANTI-BACTERIAL AGENT

D E S C R I P T I O N / M O D E O F A C T I O N

Fubac cream is a combination of anti-fungal, anti-bacterial, anti-inflammatory and anti-pruritic agents. The anti-fungal Clotrimazole, anti infective Gentamicin sulphate, anti-pruritic Iodochlorhydroxy quinoline and the anti-inflammatory class III steroid Beclomethasone dipropionate are all complementary to each other. Fubac offers foursome attack in stubborn mixed infections caused by fungi and bacteria, by the powerful synergy caused by the combination of the 4 ingredients.

C O M P O S I T I O N

Each Fubac cream contains :
Beclomethasone dipropionate 0.025% w/w
Neomycin sulphate 0.5% w/w
Clotrimazole 1% w/w
Iodochlorhydroxy quinoline 1% w/w

I N D I C AT I O N S

Fubac is specially designed for mixed fungal and bacterial infections like eczematous mycosis, intertrigo, stubborn tinea infections, allergic dermatitis super infected with fungi. The multiple ingredients in fixed dose combination in Fubac make it particularly helpful in mixed fungal bacterial infection which is difficult to diagnose clinically. Clotrimazole in Fubac is a potent anti-fungal agent which is effective not only against tinea infection but also acts against Candida. Hence Fubac is indicated in common infection like Vulvo vaginitis due to Candida encountered in gyneacological practice. Other indications include Impetigo, Furunculosis, Napkin rash, Otitis externa.

D O S A G E

To be applied sparingly 2-3 times daily on the affected area.

S I D E E F F E C T S

Chickenpox, Scabies, Herpes, Acne, Rosacea leg ulcers, Tubercular and viral skin diseases, post vaccination skin eruption, untreated bacterial and fungal infections, perioral dermatitis cah occur after continuous prophylactic use, prolonged or extensive use in pregnancy. Special precaution during withdrawal: As abrupt withdrawal after prolonged therapy may lead to rebound exacerbation of the disease, gradual withdrawal is recommended. Use in children or on face to be limited to 5 days. Growth retardation is observed in some children with prolonged use of potent steroid.

P R E S E N TAT I O N & PACK

Fubac is presented as 5 gm tube packed in a carton.


GRENIL™

The quicker, safer pain relief in migraine attack

D E S C R I P T I O N / M O D E O F A C T I O N

Grenil is a combination of Domperidone and Paracetamol. Domperidone is a benzimidazole derivative. It is a selective antagonist of the peripheral dopamine D 2 receptors in stomach and acts on chemoreceptor triggerzone (CTZ). After oral administration, Domperidone is absorbed rapidly and almost completely. The peak plasma concentrations reached within 30 minutes are 23 ng / ml after a 10 mg dose and 80 – 102 ng / ml after a 60 mg dose, Domperidone is bound to plasma proteins (91% - 93%). Roughly 1/3 rd of the administered dose is eliminated through the kidney within the first 24 hours. About 10% of the drug is excreted unchanged in faeces. The elimination half-life of Domperidone is 1.5 hours. It has antiemetic and prokinetic properties. Domperidone has no cholinomimetic (acetyl choline like) action at the peripheral muscarinic receptors. Entry of Domperidone into the CNS is poor. Domperidone constricts the lower oesophageal sphincter and relaxes the pyloric sphincter, thereby abolishes nausea, vomiting and alleviates symptoms of postprandial dyspepsia.

Paracetamol is N-acetyl-para aminophenol, has an effective analgesic and antipyretic properties. Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. The plasma concentration reaches a peak in 30 to 60 minutes and the half-life in plasma is about 2 hours. Paracetamol is relatively uniformly distributed throughout the body. Plasma protein binding is around 20% to 50%. After therapeutic doses, 90% to 100% of the drug may be recovered in the urine within the first day, primarily after hepatic metabolism.

C O M P O S I T I O N

Grenil contains : Qty. in Tab Qty. in Susp / 5 ml
Domperidone 20 mg 5 mg
Paracetamol 500 mg 250 mg

I N D I C AT I O N S

Grenil is reccommended in :
vAcute migraine attack
vTension headache
vMenstrual & Pre-menstrual cephalalgia
vChildhood migraine
vPyrexia associated with nausea and vomiting

D O S A G E

The recommended dosage is as follows :
15 Years & above : 1-2 tablets at the onset of attack, subsequently one tablet every 4 hours, if needed, not
exceeding 4 tablets per day.
12-15 Years : 1 tablet at the onset of attack, maximum 3 tablets in 24 hours.

S I D E E F F E C T S

Very rarely allergic reactions and skin rashes may occur. In a few isolated cases, Paracetamol may cause meutropenia, thrombocytopenias and pancytopenia. In adults, hepatotoxicity may occur after ingestion of a single dose of 10 to 15 gm Paracetamol, which may cause a potentially fatal hepatic necrosis. Over dosage may be treated with N-acetyl cysteine – 5% solution orally. Domperidone has been well tolerated in most cases. Occasional minor effects include dry mouth, thirst, headache, diarrhoea, nervousness & transient rash. Extra-pyramidal side effects are rare with Domperidone.

P R E S E N TAT I O N & PACK
Tablet : Strips of 10 X 10’s in Blister pack
Susp : Bottle of 60 ml


GRENIL-F™

For a comprehensive relief in Migraine management

D E S C R I P T I O N / M O D E O F A C T I O N

Flunarizine is a selective calcium antagonist. Prevents cellular calcium overload by reducing excessive transmembrane calcium influx. Its mode of action in migraine is unclear, possible mechanisms are inhibition of vasospasm induced by mediators such as serotonin & prostaglandins, inhibition of cellular hypoxia, & improved blood viscosity & erythrocyte deformability. Flunarizine by blocking calcium channels of vascular smooth muscels of the cranial arteries inhibits vasoconstriction of those arteries. This in turn avoids smooth muscle fatigue & subsequent vasodilatation.
Flunarizine is well absorbed from the gut, peak plasma levels are reached within 2-4hrs and reaching steady state at 5-6 weeks. Under goes extensive hepatic metabolism, excreted through faeces via bile. The terminal elimination half life is about 18 days. Plasma protein binding is 99%. Flunarizine crosses blood brain barrier.
C O M P O S I T I O N

Grenil F contains : Qty. in Tab
Flunarizine HCL 5 & 10 mg

I N D I C AT I O N S

Grenil F is recommended in :
vProphylaxis of migraine
vProphylaxis of vertigo & vestibular disorders
vProphylaxis of pheripheral & cerebrovascular disorders


D O S A G E

The recommended dosage is as follows :
Aduts : 10mg once a day at bedtime.
7-15 Years / <40 kg : 5mg initially & 10mg later, depending on response.

S I D E E F F E C T S
Sedation, fatigue, weight gain / increased appetite
On chronic treatment –
Depression (female patients with the history of depressive illness)
Extrapyramidal symptoms (bradykinesia, rigidity , akathisia, orofacial dyskinesia, tremor)
Porhyria
Infrequently reported adverse reaction : heartburn, nausea, gastralgia, insomnia, anxiety, galactorrhoea,
dry mouth, muscle ache

P R E S E N TAT I O N & PACK

Grenil - F 5 mg : Strips of 10 X 10’s in Blister pack
Grenil - F 10 mg : Strips of 10 X 10’s in Blister pack


GLIMKAP™

For the Improvement of Quality of life in Type 2 DM

D E S C R I P T I O N / M O D E O F A C T I O N

Glimepiride is a Sulphonylureas, cause hypoglycaemia by stimulating insulin release from pancreatic b cells. Sulphonylureas also may further increase insulin levels by reducing hepatic metabolism of the hormone. In the initial months of Sulphonylurea treatments, fasting plasma insulin levels and insulin responses to oral glucose challenges are increased. With chronic administration, circulating insulin declines to those that existed before treatment, but despite this reduction in insulin levels, reduced plasma glucose levels are maintained. The explanation for this is not clear, but it may relate to reduced plasma glucose allowing circulating insulin to have more pronounced effects on its target tissues, and to the fact that chronic hyperglycaemia per se impairs insulin secretion (Glucose toxicity)
Sulphonylureas also stimulate release of somatostatin, and they may suppress the secretion of glucagons slightly.
The effects of the Sulphonylureas are initiated by binding to and blocking an ATP-sensitive K+ channel, which has been cloned. The drugs thus resemble physiological secretagogues (e.g., Glucose, Leucine), which also lower the conductance of this channel. Reduced K+ conductance causes membrane depolarisation and influx of Ca2+ through voltage-sensitive Ca2+ channels.

C O M P O S I T I O N

Glimepiride 1mg / 2mg Tablets

I N D I C AT I O N S

Type 2 DM


D O S A G E

The recommended dosage is as follows :
1-2 mg initially, 4mg as maintenance dose, upto a maximum of 8mg per day, before the first meal.

S I D E E F F E C T S
Hypoglycaemic reactions
Coma
Nausea and vomiting
Cholestatic jaundice
Agranulocytosis
Aplastic and hemolytic anaemias
Generalized hypersensitivity reactions, and dermatological reactions.
Some drugs also, displace the Sulphonylureas from binding proteins, thereby increasing the free concentration transiently. These include other Sulfonamides, Clofibrate, Dicumarol, Salicylates, and Phenylbutazone. Ethanol may enhance the action of Sulphonylureas by causing hypoglycaemia.


P R E S E N TAT I O N & PACK

Glimkap 1mg - Strips of 10 X 10’s tablets in Blister pack
Glimkap 2mg - Strips of 10 X 10’s tablets in Blister pack


HUSKY™- NEW

A Natural Bowel Facilitator

D E S C R I P T I O N / M O D E O F A C T I O N

The active ingredient in Husky is Psyllium husk (Ispaghulla husk), a natural dietary fiber derived from Plantago ovata seeds. Psyllium husk is neither digested nor absorbed in the small intestine. The bulk forming effect is due to both the water binding capacity of undigested fiber and the increased bacterial mass following partial digestion in the colon. These actions result in distension of the colon and soften stools, thereby decreasing intraluminal pressure, straining and speeding colonic transit in constipated patients. Psyllium binds to bile acids, reducing their intestinal reabsorption and promoting their excretion. The consequent enhancement of hepatic synthesis of bile acids from cholesterol may reduce plasma cholesterol in low-density lipoproteins. With several months of use, bulk forming agents reduce intraluminal rectosigmoid pressure and relieve symptoms in patients with irritable bowel syndrome and diverticular disease of the colon. The capacity of these agents to absorb water makes them useful in relieving the symptoms of mold diarrhoea and for the regulation of effluent in patients with ileostomy or colostomy.

C O M P O S I T I O N

Ispaghulla husk powder (Psyllium husk) 64.80%
Nimbu satwa (Citric acid) 10.00%
Sarijka kshar (Sodium bicarbonate) 8.52%

I N D I C AT I O N S

vChronic constipation.
vIrritable bowel syndrome.
vHaemorrhoids and Fissures.
vHypercholesteraemia & Obesity.

D O S A G E

One teaspoonful once or twice daily along with plenty of water.

S I D E E F F E C T S

Bulk forming laxatives have very few side effects and minimal systemic effect. Allergic reactions may occur but very rarely. Flatulence and Borborygmi occur occasionally. Psyllium husk may contain significant qualities of Na + and should not be used when systemic retention of Na + and H2O is a problem. Psyllium may bind to Coumarin derivatives. Individuals with stenosis, ulceration or adhesions should avoid these agents. Oesophageal and intestinal obstruction can occur when these substances are taken without adequate fluid intake. Patients may avoid these problems by drinking a glass of water concurrently.


P R E S E N TAT I O N & PACK

Husky Granules is available in 100 gm container.
Husky Granules is available in 5 gm sachet.

KAMADOL™

The analgesic answer to severe pain

D E S C R I P T I O N / M O D E O F A C T I O N
Kamadol is Tramadol hydrochloride which is a centrally acting analgesic. The chemical name is (+) cis – 2 [(dimethylaminomethyl) – (3-methoxyphenyl)] cyclohexanol hydrochloride. The analgesic activity of tramadol is due to both parent drug and the M1 metabolite. Tramadol is well absorbed orally with an absolute bioavailability of 75%. It is only 20% bound to plasma proteins and is extensively metabolised. Tramadol and its metabolites are excreted primarily in the urine with observed plasma half lives of 6.3 and 7.4 hours for Tramadol and M1 metabolite. It is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. Tramadol is extensively metabolised in the body. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.

C O M P O S I T I O N

Each 2 ml Ampoule contains Tramadol Hcl 100 mg.
Each 1 ml Ampoule contains Tramadol Hcl 50 mg.

I N D I C AT I O N S

Tramadol is indicated for the management of moderate to moderately severe pain. It is indicated in Post operative pain due to General, Orthopedic and Gynaecological surgery. Maxillofacial and other Dental surgery. Tramadol is also indicated in Painful bone metastasis, Acute joint pains and Neuropathic pain syndromes.

D O S A G E

Adults : 100 mg o.d. or b.i.d. by I.M. / I.V.
Children: 1 mg / kg body weight by I.M. / I.V.
For the treatment of painful conditions, Tramadol 100 mg can be administered as needed for relief every four to six hours not to exceed 400 mg per day. For moderate pain, 50 mg may be adequate as the initial dose and for more severe pain, 100 mg is usually more effective as the initial dose. For elderly patients over 75 years, not more than 300 mg/day in divided doses as above is recommended.

S I D E E F F E C T S

The most frequently reported events during the double blind or open label extension periods in U.S. studies of chronic non-malignant pain were in the Central nervous system and Gastrointestinal system.

P R E S E N TAT I O N & PACK

Kamadol is presented in 2 strengths as -
Kamadol 100 : 5 X 2 ml Ampoules in a carton.
Kamadol 50 : 5 X 1 ml Ampoules in a carton.

KAMADOL™- P

For Complete Freedom From Pain

D E S C R I P T I O N / M O D E O F A C T I O N

Tramadol is a centrally acting analgesic structurally related to opioid derivatives like codeine. Tramadol acts at both spinal and supraspinal areas. It acts by two mechanisms.
By inhibiting the neuronal uptake of serotonin and norepinephrine, it reduces pain
By binding to μ opioid receptors it reduces pain.
Thus the effect of tramadol is the sum of both the above actions.

Pharmacikinetics : Tramdol is rapidly and almost completely absorbed after oral administration .
Bioavailability : 75%
Plasma protien binding : 20%
Duration of action : 6 hours
Metabolised by liver and excreted by kidney. M1 metabolite is 6 times as potent as the parent drug. This enhances the duration action. Dose may need to be adjusted in renal / hepatic failure and in very old patients
Paracetamol is a time tested analgesic antipyretic. It has weak activity on prostaglandin synthatase in the peripheral inflamed tissue. However it equals the blocking effect of aspirin on this enzyme in the brain. Therefore paracetamol is a potent antipyretic and is equianalgesic with aspirin in therapeutic doses.
Clinical efficacy : Tramodol and paracetamol in combination is incresingly becoming popular for the treatment of moderate to severe pain. Besides providing good analgesic efficacy this combination improves exercise capability in such patients


C O M P O S I T I O N

Tramadol hydrochloride – 37.5 mg
Paracetamol – 325 mg

I N D I C AT I O N S

Arthritic pain - ostearthritis, rheumatoid arthritis
Diabetic neuropathy, trigeminal neuralgia, post herpetic neuralgia.
Pain due to fractures,iolapse, burn, sciatca, past surgical pain & dental pain.
Cancer pain.

D OA G E

Moderate to Severa Pain: 1 – 2 Tablets 3 to 4 times a day.

S I D E E F F E C T S

Common side effects include nausea, vomiting, dry mouth, dizzinesss, headach and sedation.

C O N T R A I N D I C A T I O N S
Known hypersensitivity to any of the ingredients or excipients or opioids.
Acute intoxication with alcohol, hypnotics, opioids, psychoactive substances.
Concurrent intake of monoamine oxidase inhibitors (MAOIs)
Inadequately controlled epilepsy.

P R E S E N TAT I O N & PACK
Kamadol - P: 10 X 10’s Tablets in blister packs.


Kapril™

The Proven ACE inhibitor for risk reduction

D E S C R I P T I O N / M O D E O F A C T I O N

Ramipril and its active metabolitramiprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and aimals.ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimlates aldosterone secretion byhadrenal corteCE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. The effect of ramiprilnhypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypetension.
The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract. Peak plasma concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces.


C O M P O S I T I O N

Kapril 2.5 – Each Tablet contains Ramipril HCL 2.5 mg
Kapril 5 – Each Tablet contains Ramipril HCL 5 mg


I N D I C AT I O N S

vHypertension
vHeart failure
vMyocardial Infarction
vProphylaxis of cardiovascular events

D O S A G E

2.5 -10 mg per day, once daily or twice a day in divided doses.

S I D E E F F E C T S

Hypotention , Hyperkalemia, Rashes, Urticaria, Angioedema, Dysgeusia,
Headache ,dizziness ,fatigue ,asthenia, cough and impotence

P R E S E N TAT I O N & PACK

Kapril 2.5: Blister pack of 10 x 10’s Tablets
Kapril 5 : Blister pack of 10 x 10’s Tablets


Kapril™- H

The synergistic combination for heart failure

D E S C R I P T I O N / M O D E O F A C T I O N

Ramipril and its active metabolite ramiprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. The effect of ramipril on hypertension appears to result at least in part from inhibition of both tissue and circulating ACE activity, thereby reducing angiotensin II formation in tissue and plasma. While the mechanism through which ramipril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ramipril has an antihypertensive effect even in patients with low-renin hypertension.
The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract. Peak plasma concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%, about 60% of the parent drug and its metabolites are eliminated in the urine, and about 40% is found in the feces.
Hydrochlorothiazide- INHIBITORS OF NA+-CL- SYMPORT
The mechanism involves increased proximal reabsorption owing to volume depletion, as well as direct effects of thiazides to increase Ca2+ reabsorption in the DCT. In this regard, inhibition of the Na+-Cl- symporter in the luminal membrane decreases intracellular Na+ levels, thereby increasing the basolateral exit of Ca2+ via enhanced Na+-Ca2+exchange . Thiazide diuretics may cause a mild magnesuria by a poorly understood mechanism, and there is increasing awareness that long-term use of thiazide diuretics may cause magnesium deficiency, particularly in the elderly . Since inhibitors of Na+-Cl- symport inhibit transport in the cortical diluting segment, thiazide diuretics attenuate the ability of the kidney to excrete a dilute urine during water diuresis.
Oral bioavailability- 70%, plasma half life- 2.5, renal elimination

C O M P O S I T I O N

Kapril - H –Each Tablet contains Ramipril HCL 2.5 mg & Hydrochlorothiazide 12.5 mg


I N D I C AT I O N S

vResistant Hypertension
vEssential Hypertension
vHeart failure
vVascular complications in diabetes

D O S A G E

2.5 -10 mg per day, once daily or twice a day in divided doses.

S I D E E F F E C T S

Hypotention , Hyperkalemia, Rashes, Urticaria, Angioedema, Dysgeusia,
Headache ,dizziness ,fatigue ,asthenia, cough and impotence
Hypokalemia, acute saline depletion, dilutional hyponetremia, hearing loss, hyperuricaemia,

P R E S E N TAT I O N & PACK

Kapril - H: Blister pack of 10 x 10’s Tablets


Lotace™

The Comprehensive Management of Hypertension

D E S C R I P T I O N / M O D E O F A C T I O N

Losartan potassium, the first of a new class of antihypertensives, is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1[p-(o-1H-tetrazol-5-dylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan.


C O M P O S I T I O N

Lotace 25 – Each Tablet contains Losartan Potassium 25 mg
Lotace 50 – Each Tablet contains Losartan Potassium 50 mg


I N D I C AT I O N S

Mild to moderate essential hypertension
Cardiac failure
Diabetic nephropathy
Left Verntricular dysfuction
Myocardial infarction

D O S A G E

Lotace 25 / 50 : One tablet once or twice daily

S I D E E F F E C T S

Fetopathic potential – Not to be administered during pregnancy.
Angioedema is reported in few cases, Headache, dizziness, weakness, upper GI side effects are mild.

P R E S E N TAT I O N & PACK

Lotace 25 : Blister pack of 10 x 10’s Tablets
Lotace 50 : Blister pack of 10 x 10’s Tablets


Lotace™ 50 - H

The Composite Management of Hypertension

D E S C R I P T I O N / M O D E O F A C T I O N

Losartan potassium, the first of a new class of antihypertensives, is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1[p-(o-1H-tetrazol-5-dylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan.
Hydrochlorothiazide- INHIBITORS OF NA+-CL- SYMPORT
The mechanism involves increased proximal reabsorption owing to volume depletion, as well as direct effects of thiazides to increase Ca2+ reabsorption in the DCT. In this regard, inhibition of the Na+-Cl- symporter in the luminal membrane decreases intracellular Na+ levels, thereby increasing the basolateral exit of Ca2+ via enhanced Na+-Ca2+exchange . Thiazide diuretics may cause a mild magnesuria by a poorly understood mechanism, and there is increasing awareness that long-term use of thiazide diuretics may cause magnesium deficiency, particularly in the elderly . Since inhibitors of Na+-Cl- symport inhibit transport in the cortical diluting segment, thiazide diuretics attenuate the ability of the kidney to excrete a dilute urine during water diuresis.
Oral bioavailability- 70%, plasma half life- 2.5, renal elimination

C O M P O S I T I O N

Lotace 50 – H – Each Tablet contains Losartan Potasium 50 mg & Hydrochlorothiazide 12.5 mg


I N D I C AT I O N S

vModerate to severe essential hypertension
vCardiac failure
vDiabetic nephropathy
vLeft Verntricular dysfuction
vMyocardial infarction

D O S A G E

Lotace 50 – H : One tablet daily

S I D E E F F E C T S

Fetopathic potential – Not to be administered during pregnancy.
Angioedema is reported in few cases, Headache, dizziness, weakness, upper GI side effects are mild.
Hypokalemia, acute saline depletion, dilutional hyponetremia, hearing loss, hyperuricaemia,

P R E S E N TAT I O N & PACK

Lotace 50 – H: Blister pack of 10 x 10’s Tablets

LOWDOL™
The total care antispasmodic analgesic

D E S C R I P T I O N / M O D E O F A C T I O N

Lowdol is a triple action antispasmodic analgesic with a combination of Dicyclomine Hydrochloride, Diclofenac Sodium and Paracetamol. Dicyclomine is an antispasmodic and anticholinergic agent, relieves smooth muscle spasm of the gastro intestinal tract, biliary tract, urinary tract and of the uterus. This has dual mechanism,
[1] A specific anticholinergic (antimuscarinic) effect at the acetylcholine receptor sites and
[2] A direct effect on the smooth muscles as evidenced by Dicyclomine’s antagonism of bradykinin and histamine induced spasms. Dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60 Ś 90 minutes. The principle route of excretion is via the urine [79. 55%]. Excretion also occurs in the faeces, but to a lesser extent [8.4%]. It has two phases elimination half-life, with a first plasma half-life of 1.8 hours and second phase elimination with a somewhat longer half-life. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 l/kg suggesting extensive distribution in tissues. Diclofenac Sodium has analgesic, antipyretic and anti-inflammatory activities. It is an inhibitor of cyclo & lipo oxygenase pathways. Diclofenac is rapidly & completely absorbed after oral administration, peak plasma concentration is reached within 2 to 3 hours. Diclofenac undergoes first pass metabolism and only 50% is available systemically. Diclofenac is extensively bound to plasma protein (99%) and its half-life in plasma is 1 to 2 hours. After oral administration it is metabolised in the liver to 4-hydroxy Diclofenac, the principle metabolite and other hydroxylated forms. The metabolites are excreted in the urine (65%) and bile (35%). Paracetamol, (N-acetyl-p-aminophenol) has analgesic and anti pyretic effects. Paracetamol is rapidly and almost completely absorbed from the GI tract. The peak plasma concentration is reached in 30 to 60 minutes and half-life in plasma is about 2 hours. Paracetamol is relatively uniformly distributed throughout the body. Plasma protein binding is around 20% to 50%. After therapeutic doses, 90% to 100% of the drug may be recovered in the urine within the first day, primarily after hepatic metabolism. A small proportion of Paracetamol undergoes cytochrome P450 Ś mediated N-hydroxylation to form N-acetylbenzoquinoneimine, a highly reactive intermediate. This metabolite is neutralised by the sulfhydryl groups in glutathione.

C O M P O S I T I O N

Each uncoated tablet of Lowdol contains : Dicyclomine Hydrochloride - 20 mg
Diclofenac Sodium - 50 mg
Paracetamol - 330 mg

I N D I C AT I O N S

LOWDOL tablet in indicated in : Intestinal colic, Ureteric colic, Biliary colic,
Spasmodic Dysmenorrhoea, Irritable bowel syndrome.
D O S A G E

The recommended dosage is 1 tablet three times a day.

S I D E E F F E C T S

In general, Lowdol is well tolerated except for rare cases of allergic reactions and skin rashes. In a few isolated cases, Paracetamol may cause neutropenia, thrombocytopenia and pancytopenia. In adults, hepatotoxicity may occur after ingestion of a single dose of 10 to 15 gm of Paracetamol, which may cause a potentially fatal hepatic necrosis. Over dosage may be treated with N-acetyl cystein-5% solution orally. Side effects like dry mouth, dizziness, nervousness may occur rarely with Dicyclomine. Side effects with Diclofenac are not common, rare cases of gastro intestinal disturbances, bleeding and ulceration or perforations of intestinal wall have been observed. other untoward responses include CNS effects, skin rashes, allergic reactions, fluid retention, odema and rarely renal impairment. Lowdol is not recommended for children, nursing mothers and pregnant women.

P R E S E N TAT I O N & PACK
Strips of 10 x 10’s in blister pack.

Maxiflam™

An enzyme specific & tissue protective non-steroidal anti-inflammatory agent

D E S C R I P T I O N / M O D E O F A C T I O N
Maxiflam is Nimesulide, a Sulfanilide compound as the acidic group. The anti inflammatory analgesic and anti-pyretic properties of Maxiflam have been demonstrated well. Maxiflam selectively inhibits the formation of pro-inflammatory prostaglandins i.e. Cyclooxygenase-2 [COX2] and spares gastro protective prostaglandins i.e. cyclooxygenase-1 [COX1].

C O M P O S I T I O N

Each uncoated tablet of Maxiflam contains Nimesulide 100 mg.
Each 5ml of suspension contains Nimesulide 50 mg.

I N D I C AT I O N S

Maxiflam tablet is indicated mainly in chronic osteoarthritis, rheumatoid arthritis, reiters syndrome, pelvic inflammatory disorders and general, ENT, Dental and Urological surgeries. Maxiflam suspension is indicated in hyperpyrexia, sports injuries, pre & post-operative conditions.

D O S A G E

Tablet : 1 tablet 3-4 times daily
Syrup : Children 2.5 ml – 5 ml thrice daily
Adults 5 ml – 10 ml thrice daily

C O N T R A I N D I C A T I O N S

Generally Maxiflam is well tolerated because of its supereior safety profile. Maxiflam is contra indicated in hypersensitivity, active peptic ulcer disease, moderate and severe hepatic impairment. Proper care has to be taken in conditions of impaired renal function, congestive cardiac failure, cirrhosis of liver. The safety of Maxiflam is not yet been established in pregnancy and lactation.

S I D E E F F E C T S

The most frequent adverse effects are those related to the digestive system, skin and nervous system. Heart burn and other gastro intestinal disturbances have been the most common unwanted effects. Occasionally, excessive perspiration, flushing, hyper excitability, skin rash, erythema and sleep disorders have been reported.

DRUG INTERACTIONS

Maxiflam may decrease the oral bioavailability of Frusemide. Maxiflam may be displaced from binding sites by concurrent administration of drugs, such as fenofibrate, salicylic acid, valproic acid, tolbutamide, methotrexate and frusemide. Maxiflam may marginally decreasse plasma theophylline level. Coagulation status to be monitored when Maxiflam and Warfarin are administered together. Maxiflam may increase the hypoglycaemic effect of glibenclamide. Caution should be exercised when Maxiflam is used in combination with drugs that are known to adversely affect renal haemodynamics.

P R E S E N TAT I O N & PACK

Strips of 10 x 10’s uncoated tablets in blister pack.
Suspension of 60 ml with measuring cup.


MAXIFLAM - SP™

The anti inflammatory par excellence with specific advantages

D E S C R I P T I O N / M O D E O F A C T I O N
Maxiflam-SP is a combination of Nimesulide, a sulfanilide compound which is a selective COX2 inhibitor sparing gastroprotective prostaglandins i e COX1, and Serratiopeptidase, a proteolytic enzyme which degrades proteins, reduces inflammation, oedema and hydrolyses bradykinin, histamine and serotonin. These substances cause dilatation of blood vessels. By hydrolysing these substances serratiopeptide indirectly reduces dilation of blood vessels and also blocks plasmin inhibitors, thus helping fibrinolytic activity of plasmin. Degradation of extrafibrin to small fragments prevents clogging of micro capillaries, reduces walling of effects, helps clear exudate, reduces swelling and improves micro-circulation.

C O M P O S I T I O N

Each enteric coated tablet contains : Nimesulide 100 mg + Serratiopeptidase 10 mg

I N D I C AT I O N S

Maxiflam - SP provided effective anti-inflammatory care in :
Trauma, injury and post surgical inflammation, Carpal Tunnel syndrome,
Bronchiectasis & bronchitis, Keratitis and Uveitis,
Pericoronitis and Alveolar abscess, Breast engorgement,
Acute and chronic sinusitis, Tonsillectomy, Otitis media,
Periodontites, Lateral episiotomy, Perincal laceration,
Salphingitis, Cystitis, Epidydemitis, Urethritis
Incomplete expectoration of sputum in bronchitis, pulmonary tuberculosis, bronchial asthma.

D O S A G E

The recommended dosage for adults is 1 tablet twice daily and should be taken / swallowed after meal.

DRUG INTERACTIONS

Generally, Maxiflam SP is well tolerated. Occasionally it may cause gastro intestinal effects such as anorexia, gastric discomfort and nausea. Hypersensitivity reactions may occur rarely.
Fenofibrate, Salicylic acid, Valproic acid and Tolbatumide : These drugs displace Nimesulide from the plasma binding sites.
Methotrexate and Frusemide : These drugs may be displaced from plasma proteins by Nimesulide.
Warfarin : Excercise caution since efficacy may be increased.
Theophyllin : Efficacy of slow release theophyllin preparations reduced.


P R E S E N TAT I O N & PACK
Strips of 10 x 10’s uncoated tablets in aluminium foil pack.

Numol™

The most potent dual acting analgesic and anti inflammatory agent

D E S C R I P T I O N / M O D E O F A C T I O N
Numol is an excellent combination of Diclofenac Sodium and Paracetamol. Diclofeanc Sodium is the most potent anti infammatory analgesic and Paracetamol is known to be the safest and effective anti pyretic. Put together, both exert a potent analgesic, anti-inflammatory and anti pyretic effects. Numol attacks pain centrally and fights pain and inflammation peripherally. While both Paracetamol and Diclofenac are known for their proven efficacy a specially designed formulation of Numol has further made it convenient, safe and effective. While Plasma concentration of Paracetamol is achieved in half - an hour, mean plasma concentration for Diclofenac Sodium at 50 mg dose is achieved 0.7 - 1.5 mg / lit. Numol is well absorbed from G.I. tract and is well tolerated.

C O M P O S I T I O N

Each tablet of Numol contains
Diclofenac Sodium (enteric coated) 50 mg and Paracetamol (film coated) 325 mg

I N D I C AT I O N S

Numol is indicated in aches and pains in day to day situations, sprains and strains, soft tissue injury, dysmenorrhoea, low back pain and dental pain.

D O S A G E

2-3 tablets / day in divided doses for adults

S I D E E F F E C T S

Generally Numol is well tolerated. Very rarely patients may complain of gastric irritation, dyspepsia or ulcers. Hypersensitivity, hepatic damage or haematological cases like agranulocytosis, bone marrow suppression, pancytopenia, aphasia are seen in longterm usage. Likely interactions with antacids, lithium, digoxin. Children under 2 years show decreased metabolism of Numol.

P R E S E N TAT I O N & PACK

Strips of 10x10’s tablets in blister pack

Numol™- A

For Freedom Of Movement In Painful Conditions

D E S C R I P T I O N / M O D E O F A C T I O N
Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of action
v Directly blocks PGE 2 secretion at the site of inflammation by inhibiting IL-Beta & TNF in the inflammatory cells
v blocks degeneration and stimulates synthesis of extracellular matrix of cartilages by inhibiting the action of different cytokines.
v inhibit IL-6 production by human chondrocytes.
v suppression of GAG [Glucosaminoglycan] and collagen synthesis and stimulates growth factor mediated synthesis of GAG and collagen.
v inhibits Neutrophil Adhesion & Accumulation at the inflammatory site in the early phase and thus blocks the pro-inflammatory actions of Neutrophils.
Well absorbed from GIT, peak plasma concentration are reached 1-3 hr, 99% plasma protein bound, Plasma elimination half-life is approximately- 4hrs
Paracetamol : The plasma elimination half-life ranges from 1 to 4 hours for paracetamol. Paracetamol is distributed throughout most fluids of the body, and is metabolized primarily in the liver. Little unchanged drugs are excreted in the urine, but most metabolic products appear in the urine within 24 hours.

C O M P O S I T I O N

ACECLOFENAC 100mg + PARACETAMOL 500mg TABLETS

I N D I C AT I O N S

vOsteoarthritis & Rheumatoid arthritis
vAnkylosing spondylitis
vPost operative & Dental pain
vGonalgia [Pain in the knee] & Lumbago [Low back Pain]
vGynaecological inflammatory conditions
vENT inflammatory conditions
vDysmenorrhoea

D O S A G E

NUMOL – A: 1 – 2 TABS PER DAY

S I D E E F F E C T S

NUMOL – A is generally well tolerated and has got a superior side effects profile as compared to other NSAIDS. However, it must be used with caution in patients with peptic ulcers, hyper acidity, severe hepatic, cardiac or renal insufficiency. Numol - A can not be used with triametrene and methotrexate and children less than 18 months of age. It is to be used with care in pregnant / lactating women.
Leukocytoclastic vasculitis & haemoptysis

P R E S E N TAT I O N & PACK
NUMOL – A Tablet - Strips of 10x10’s in blister packs


Nufenac™

The most potent non-steriodal anti-inflammatory agent

D E S C R I P T I O N / M O D E O F A C T I O N
Nufenac is Diclofenac Sodium the ‚first choice drug in the treatment of acute and chronic painful inflammatory conditions. Diclofenac Sodium is a Phenyl Acetic Acid derivative. It is well absorbed by oral, rectal, locally and IM routes. The peak plasma concentration is achieved in 10-30 minutes by IM route and 1.5-2.5 hours by oral route. The protein binding is as high as 99.5% . It has a short elimination half-life of 1.1 - 1.8 hours, therefore it does not accumulate. High concentration is seen in synovial fluid. Plasma clearance is 16 litres / hour. It can cross placenta and may be present in milk. Diclofenac acts by inhibiting cyclo and lypo oxygenase. Generally it is well tolerated and has a good therapeutic index, like low ulcerogenic activity and low gastric transmural potential.

C O M P O S I T I O N

Nufenac Ampoule : Each 3ml ampoule contains Diclofenac Sodium 75 mg
Nufenac Tablet : Each enteric coated tablet contains Diclofenac Sodium 50 mg
Nufenac SR : Each sustained release tablet contains Diclofenac Sodium 100 mg
Nufenac Gel : Each 20 gm tube contains Diclofenac Diethyl ammonium 1.16% w/w

I N D I C AT I O N S

Nufenac Injection can be recommended for acute painful states, renal and biliary colic and pre & post operative pain.
Nufenac Tablet is indicated in acute painful inflammatory conditions of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis etc.
Nufenac SR Tablet is indicated in chronic painful inflammatory conditions.
Nufenac Gel is indicated for symptomatic relief of pain and inflammation locally in sprains, strains, bursitis, thrombophlebitis and during physiotherapy.

D O S A G E

In children - 0.25-0.5 mg / kg
Adults - 50-100 mg in 2-3 divided doses
Nufenac Inj. - 1-2 ampoule/day depending on the severity
Nufenac tablet - 75-150 mg daily in 2-3 divided doses
Nufenac SR - 100-200 mg daily in 1-2 divided doses

S I D E E F F E C T S

Nufenac is generally well tolerated and has got a superior side effects profile as compared to other NSAIDS. However, it must be used with caution in patients with peptic ulcers, hyper acidity, severe hepatic, cardiac or renal insufficiency. Nufenac can not be used with triametrene and methotrexate and children less than 18 months of age. It is to be used with care in pregnant / lactating women.

P R E S E N TAT I O N & PACK

Nufenac Injection - Each ampoule of 3 ml contains Diclofenac Sodium 75 mg
Nufenac Tablet / SR Tablet - Strips of 10x10’s in blister packs
Nufenac Gel - Each tube of 20 gm


Nufenac™- A

For Freedom Of Movement In Inflammatory Conditions

D E S C R I P T I O N / M O D E O F A C T I O N
Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of action
v Directly blocks PGE 2 secretion at the site of inflammation by inhibiting IL-Beta & TNF in the inflammatory cells
v blocks degeneration and stimulates synthesis of extracellular matrix of cartilages by inhibiting the action of different cytokines.
v inhibit IL-6 production by human chondrocytes.
v suppression of GAG [Glucosaminoglycan] and collagen synthesis and stimulates growth factor mediated synthesis of GAG and collagen.
v inhibits Neutrophil Adhesion & Accumulation at the inflammatory site in the early phase and thus blocks the pro-inflammatory actions of Neutrophils.
Well absorbed from GIT, peak plasma concentration are reached 1-3 hr, 99% plasma protein bound, Plasma elimination half-life is approximately- 4hrs

C O M P O S I T I O N

ACECLOFENAC 100 mg / 200 mg TABLETS

I N D I C AT I O N S

Acute painful states, renal and biliary colic and pre & post operative pain.
Acute painful inflammatory conditions of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis etc.
Chronic painful inflammatory conditions.
Symptomatic relief of pain and inflammation locally in sprains, strains, bursitis, thrombophlebitis and during physiotherapy.

D O S A G E

Adults – 100-200mg in 2-3 divided doses


S I D E E F F E C T S

Nufenac – A is generally well tolerated and has got a superior side effects profile as compared to other NSAIDS. However, it must be used with caution in patients with peptic ulcers, hyper acidity, severe hepatic, cardiac or renal insufficiency. Nufenac – A can not be used with triametrene and methotrexate and children less than 18 months of age. It is to be used with care in pregnant / lactating women.
Leukocytoclastic vasculitis & haemoptysis

P R E S E N TAT I O N & PACK

Nufenac A Tablet - Strips of 10x10’s in blister packs

OLIGEL™
Fast acting topical gel for musculoskeletal injuries

D E S C R I P T I O N / M O D E O F A C T I O N

Oleum Lini is a yellowish with peculiar odour and bland taste. It is used as an emollient. Oleum Lini contains predominantly essential fatty acids i.e. a-Linolenic anid. On percutaneous absorption a-Linolenic acid is converted to Eicosapentanoic acid [EPA]. EPA is acted upon by cyclo-oxygenase enzyme to produce prostaglandin E3 that is a weak inflammatory agent. Presence of EPA prevents the action of cyclo-oxygenase on arachidonic acid, thus reducing its conversion to PGE2 (a highly inflammatory agent).
Methyl salicylate (Oil of Wintergreen) is a colourless or pale yellow or reddish liquid with a strong characteristic aromatic odour. Very slightly soluble in water, soluble in 1 in 7 of alcohol (70%). Methyl salicylate is a known anti-inflammatory agent. Menthol is a colourless, prismatic crystal or crystalline powder with a penetrating odour. Menthol is slightly soluble in water, very soluble in alcohol, chloroform and ether. After absorption, menthol is excreted in the urine and bile as a glucoronide metabolite.

C O M P O S I T I O N

Each Oligel cream contains :
Oleum Lini (Linseed Oil) 3.00% w/w
Diclofenac diethyl ammonium 1.16% w/w
Methyl salicylate 10.00% w/w
Menthol 5.00% w/w

I N D I C AT I O N S

Oligel is indicated for the quick relief from pain, swelling and inflammation due to musculoskeletal disorders such as sprains, strains, tendonitis, bursitis, hand,neck and shoulder pain, sciatica, muscle stiffness, joint pain, back ache and lumbago.

P R E S E N TAT I O N & PACK

Each Oligel cream tube is available as 30 gm, packed in a carton.

Pertenol™

The ‘Perfect – Ten’ Antihypertensive

D E S C R I P T I O N / M O D E O F A C T I O N

Pertenol is Atenolol, a cardio selective adreno receptor blocking agent. Pertenol is an effective and a well tolerated beta blocker having certain distinct advantages, especially in the treatment of hypertension. Pertenol reduces both systolic and diastolic blood pressure. Pertenol is rapidly absorbed from G.I. tract. Pertenol does not undergo first pass hepatic metabolism. Being hydrophyllic, Pertenol is free from disturbing CNS side effects. It is widely distributed in the body. However, only a small portion of Pertenol is excreted in urine unchanged. Pertenol diffuses across the placenta is excreted in breast milk.

C O M P O S I T I O N

Each scored tablet of Pertenol contains - Atenolol 50 mg

I N D I C AT I O N S

Pertenol is indicated in the management of hypertension, angina pectoris, cardiac arrhythmia and hyperthyroidism.

D O S A G E

50 – 100 mg once daily or as directed by the physician. Increasing the dose beyond 100 mg a day does not likely to produce any further benefit. In patients with impaired renal function dosage should be individualised on the basis of renal function tests. For those patients whose glomerular filtration rate is between 10 and 30 ml per minute (or serum creatinine is between 2.5 & 5 mg per 100 ml on at least two occasions), 50 mg Pertenol per day is recommended.

S I D E E F F E C T S

Pertenol is generally well tolerated. The common side effects include diarrhoea, fatigue and cold extremities. Vivid dreams and insomnia have reported occasionally. Bronchospasm has been seen in a few patients and therefore, appropriate precaution may be taken.

P R E S E N TAT I O N & PACK

Tablets 50 mg - Strips of 10x14’s scored tablets in blister pack.


Pertenol™

The ‘Perfect – Ten’ Antihypertensive

D E S C R I P T I O N / M O D E O F A C T I O N

Pertenol is Atenolol, a cardio selective adreno receptor blocking agent. Pertenol is an effective and a well tolerated beta blocker having certain distinct advantages, especially in the treatment of hypertension. Pertenol reduces both systolic and diastolic blood pressure. Pertenol is rapidly absorbed from G.I. tract. Pertenol does not undergo first pass hepatic metabolism. Being hydrophyllic, Pertenol is free from disturbing CNS side effects. It is widely distributed in the body. However, only a small portion of Pertenol is excreted in urine unchanged. Pertenol diffuses across the placenta is excreted in breast milk.

C O M P O S I T I O N

Each scored tablet of Pertenol contains - Atenolol 50 mg

I N D I C AT I O N S

Pertenol is indicated in the management of hypertension, angina pectoris, cardiac arrhythmia and hyperthyroidism.

D O S A G E

50 – 100 mg once daily or as directed by the physician. Increasing the dose beyond 100 mg a day does not likely to produce any further benefit. In patients with impaired renal function dosage should be individualised on the basis of renal function tests. For those patients whose glomerular filtration rate is between 10 and 30 ml per minute (or serum creatinine is between 2.5 & 5 mg per 100 ml on at least two occasions), 50 mg Pertenol per day is recommended.

S I D E E F F E C T S

Pertenol is generally well tolerated. The common side effects include diarrhoea, fatigue and cold extremities. Vivid dreams and insomnia have reported occasionally. Bronchospasm has been seen in a few patients and therefore, appropriate precaution may be taken.

P R E S E N TAT I O N & PACK

Tablets 50 mg - Strips of 10x14’s scored tablets in blister pack.


Piokap™

FOR EFFECTIVE GLYCAEMIC CONTROL & REVERSAL OF INSULIN RESISTANCE

D E S C R I P T I O N / M O D E O F A C T I O N

Piokap is only Pioglitazone. Pioglitazone belongs to thiazolidinedione group of oral diabetic drugs, that has been developed for the treatment of type 2 diabetes mellitus. It acts by binding with high affinity to and activates the nuclear Peroxisome Proliferator Activated Receptor – Γ (PPAR Γ) enhancing or correcting the intracellular signaling chain induced by insulin. Expression of the glucose transporter protein GLUT 1 and GLUT 4 was increased by 10 fold after Pioglitazone administration. It thus increases transcription of various proteins, amplifies post receptor action of insulin, restores glucose transportation by inhibiting gluconeogenesis and ensures effective glycaemic control in insulin resistant type 2 diabetes mellitus.It exhibits beneficial role in hypotensive patients, do not induce hypoglycaemia and reduces hyperinsulinaemia.

C O M P O S I T I O N

Piokap – Each film coated tablet contains: Pioglitazone 15 mg / 30 mg.

I N D I C AT I O N S

Piokap is indicated in Insulin resistant Type 2 diabetes mellitus.

D O S A G E

Piokap – Usual recommended is 15 mg or 30 mg once daily and maximum of 45 mg / day once.
It can be taken irrespective of meal time and no dosage titration is required in the elderly or patients with moderate renal impairment. It can be safely co-administered with Metformin, Sulphonylureas & Glucosidase inhibitors and even Insulin.

S I D E E F F E C T S

Apart from edema the following adverse events were reported – URTI, headache, sinusitis, myalgia, tooth disorder and pharyngitis.

P R E S E N TAT I O N & PACK

Piokap 15 : Tablets of 10 X 10’s blister pack..
Piokap 30 : Tablets of 10 X 10’s blister pack.



Piokap™ – MF

FOR EFFECTIVE GLYCAEMIC CONTROL & REVERSAL OF INSULIN RESISTANCE

D E S C R I P T I O N / M O D E O F A C T I O N

Piokap – MF is combination of Pioglitazone and Metformin. Pioglitazone belongs to thiazolidinedione group of oral diabetic drugs, that has been developed for the treatment of type 2 diabetes mellitus. It acts by binding with high affinity to and activates the nuclear Peroxisome Proliferator Activated Receptor – Γ (PPAR Γ) enhancing or correcting the intracellular signaling chain induced by insulin. Expression of the glucose transporter protein GLUT 1 and GLUT 4 was increased by 10 fold after Pioglitazone administration. It thus increases transcription of various proteins, amplifies post receptor action of insulin, restores glucose transportation by inhibiting gluconeogenesis and ensures effective glycaemic control in insulin resistant type 2 diabetes mellitus.It exhibits beneficial role in hypotensive patients, do not induce hypoglycaemia and reduces hyperinsulinaemia. Its combination with Metformin resulted in statestically significant drop in triglyceride levels and improvement in lipid profiles by increasing the mean HDL cholesterol level.

C O M P O S I T I O N

Piokap – MF: Each film coated tablet contains: Pioglitazone 15 mg.
Metformin 500 mg.

I N D I C AT I O N S

Piokap – MF is indicated in Insulin resistant Type 2 diabetes mellitus and PCOD.
Piokap – MF is recommended in patients where there is inadequate control with monotherapy.

D O S A G E

Piokap – MF : Usually 1 tablet per day before breakfast. Metformin or other oral antidiabetic drug may be added depending on the glycaemic control.

S I D E E F F E C T S

Lactic acidosis, Vitamin 12 deficiency are most common. Less frequent adverse effects are oedema, URTI, headache, sinusitis, myalgia, tooth disorder and pharyngitis.

P R E S E N TAT I O N & PACK

Piokap – MF : Tablets 10 x 10’s in blister pack.

KAPROLAM ™

A Better Answer To Problems Of Anxiety States

D E S C R I P T I O N / M O D E O F A C T I O N
Kaprolam is a triazolobenzodiazepine which is unusaul among benzodiazepines. In Alprazolam, a triazoloring is fused to positions 1 and 2, possesses anxiolytic, muscle relaxing, anticonvulsant and sleep modifying actions. Additionally it has antidepressant action. Alprazolam is readily absorbed after oral administration. peak plasma levels are reached in 1 to 2 hours, and are propotional to the dose in the range of 0.5 to 3.0 mg. Absolute bioavailability apperar to be at least 80%. Alprazolam and its metabolites are widely distributed throughout the body, binding to plasma proteins is about 70%. It crosses the placenta and is excreted into the breast milk. Alprazolam is metabolised extensively with atleast 29 metabolites. One of these metabolites, alpha-hydroxyalprazolam has about half the activity of the parent compound. About 20% of the dose is excreted as unchanged Alprazolam primarily in the urine along with the metabolites. The elimination half-life is about 10-12 hours.

C O M P O S I T I O N
Each uncoated tablet contains : Alprazolam 0.25 mg / 0.5 mg

I N D I C AT I O N S
Alprazolam is indicated in the management of the following clinical conditions:
1. Generalised anxiety disorders
ii. Phobic anxiety disorders
iii. Panic states with or without agoraphobia
iv. Depression associated with anxiety

D O S A G E
Dosage of Alprazolam should be individualised.
Anxiety disorders : Alprazolam can be started at 0.25 or 0.5 mg, three times a day. The dose may be
increased at intervals of 3-4 days upto a maximum daily dose of 4 mg given in divided
doses. In elderly patients with severe liver disease or debilitating disease, the starting
dose is 0.25 mg given two or three times a day.
Phobic disorders : Alprazolam in a dose of 0.5 to 3 mg can be helpful in reducing fearful avoidance.
Panic disorders : Generally higher daily doses have been needed to manage panic disorders. Alprazolam
is started at 0.5 mg three times a day. Depending on the response, the dose may be
increased by 1 mg / day at intervals of 3-4 days. The total daily dose should be
distributed evenly during the waking hours in 3 or 4 divided doses.
Depression : Alprazolam dosage is similar toother doses used for anxiety disorders. The starting
dose may be 0.5 mg three times a day increased as required up to 4 mg / day in divided
doses.
Discontiuity : While discontinuing Alprazolam, dosage reduction should be gradual 0.5 mg in every 3
days.

C O N T R A I N D I C A T I O N S
Alprazolam is contraindicated in patients with known hypersensitivity to it. It is also containdicated in patients with acute narrow angle glaucoma who are being treated appropriately. Alprazolam is contraindicated during pregnancy and lactation. It is also not recommended for use in patients below 18 years. Alprazolam is contraindicated in patients with nyasthenia gravis.

S I D E E F F E C T S
Drowsiness, dizziness, depression, headache, akathisia, increased salivation and hypotension.

P R E S E N TAT I O N & PACK
Strips of 10 x 10’s in blister pack for both 0.25 mg and 0.5 mg.


Rem-CC™

A Ready Remedy For Cough & Cold

D E S C R I P T I O N / M O D E O F A C T I O N

Rem-CC is a unique combination for cough and cold conditions. Because of the added advantage of Paracetamol, an aminophenol derivative as an antipyretic and helps even in febrile conditions during cough and cold. A proven mucolytic expectorant Bromhexine HCl, a synthetic derivative of adhatoda vasica, with a nasal decongestant, Phenyl Propalanomine, a sympathomimetic agent and in addition, a classical antihistamine, Chlorpheniramine Maleate H1 -receptor antagonist makes Rem-CC an excellent remedy for cough and cold.


C O M P O S I T I O N

Each 5ml of Rem-CC syrup contains : Bromhexine HCl – 4 mg
Phenylephrine HCl – 2.5 mg
Chlorpheniramine Maleate – 2 mg
Paracetamol – 125 mg

Each Rem-CC tablet contains : Bromhexine HCl – 8 mg
Phenylephrine HCl – 5 mg
Chlorpheniramine Maleate – 2 mg
Paracetamol – 500 mg

I N D I C AT I O N S

Rem-CC is indicated in cough, cold, coryza with febrile conditions.

D O S A G E

Tablet : 1 tablet 3-4 times daily
Syrup : Children 2.5 ml – 5 ml thrice daily
Adults 5 ml – 10 ml thrice daily

S I D E E F F E C T S

Rem-CC is well tolerated generally, occasional G.I. Tract irritation is observed.

P R E S E N TAT I O N & PACK

Bottle of 60 ml with measuring cup.
Box of 10x10’s tablets in blister strips.




RemCC™- XP

An Excellence in Airway Passage

D E S C R I P T I O N / M O D E O F A C T I O N

RemCC- XP is a unique combination for cough with sputum. Expectorants are drugs believed to increase bronchial secreation or reduce its viscosity, facilitating its removal by coughing.
Ambroxol is a metabolite of bromhexine having potent mucolytic & mucokinetic , capable of inducing thin copious bronchial secretion . It depolymerises mucopolysaccharides directly or indirectly by liberating lysosomal enzymes . Ambroxyl also poses anti inflammatory, anti oxidant & local anaesthetic activity.


C O M P O S I T I O N

Each 5ml of RemCC XP syrup contains : Ambroxol Hydrochloride – 30 mg
Terbutaline Sulphate – 1.5 mg
Guiaphenesin – 50 mg
Mentholated Syrup Base


I N D I C AT I O N S

vBronchial Asthma
vBronchitis & Bronchiectasis
vCongestive conditions

D O S A G E

Syrup : Children 2.5 ml – 5 ml thrice daily
Adults 5 ml – 10 ml thrice daily

S I D E E F F E C T S

Remcc - XP is well tolerated generally, occasional G.I. Tract irritation is observed.

P R E S E N TAT I O N & PACK

Bottle of 60 ml with measuring cup.


TOPRAZOL™

A step above the conventional management of Acid Peptic Diseases

D E S C R I P T I O N / M O D E O F A C T I O N

Toprazol (Pantoprazole) is a pyridyl methylsulfinyl benzimidazole, which causes irreversible inhibition of proton pump (H+K+-AT Pase) function. Pantoprazole after absorption from the upper intestine enters the blood stream. From here it enters the parietal cell, crosses the cell membrane and gets concentrated in the canaliculi. In the canaliculi, because of the strong acidic condition it gets converted to sulphenamide derivatives. The sulphinamide derivatives of pantoprazole inactivate the sulfhydryl group of H+K+Adenosine Tri-Phosphatase ( A T Pase), which in turn catalyses the final step of the gastric acid secretion pathway, thus inhibiting both centrally and peripherally mediated gastric acid secretion. It is rapidly activated under strongly acidic conditions. This pH dependent activation profile underlines the in-vitro selectivity of pantoprazole against H+K+ AT Pase compared with Omeprazole. Pantoprazole is rapidly absorbed after oral administration with peak plasma concentration of 1.1 to 3.1 mg / L (Cmax) occuring 2 to 4 hours (Tmax) after ingestion of an enteric coated 40 mg tablet. The drug is subject to low hepatic extraction, displaying an estimated absolute bioavailability of 77%. Elimination half-life of Pantoprazole is 0.9 to 9 hours. However inhibition of acid secretion, once accomplished, persists long after the drug has been cleared from the circulation and has a plasma protein binding of 98%. Pantoprazole undergoes extensive hepatic metabolism via cytochrome p 450 mediated oxidation followed by sulphate conjugation. Elimination is predominantly renal with 80% of an oral or intravenous dose being excreted as urinary metabolites, the remainder is excreted in the faeces and originates primarily from biliary secretion.

C O M P O S I T I O N

Each tablet of Toprazol contains : Pantoprazole 40 mg

I N D I C AT I O N S

Pantoprazole is indicated for the treatment of acid related disorders like :
i. Gastric and duodenal ulcers
ii. Reflux Oesophagitis
iii. Zollinger-Ellison syndrome
iv. For the eradication of H. Pylori, it can be combined with other antibacterial agents.
v. Treatment of ulcers resistant to H2 antagonists.
vi. Maintenance of ulcer remission
vii. Treatment of ulcers induced by NSAIDs
viii. Treatment of non ulcer dyspepsia
ix. Bleeding ulcers

D O S A G E

It is given orally in a dose of 40 mg once daily before breakfast. Dosage adjustment is not required in the eldrly and in patients with renal impairment or in those with hepatic impairment.

S I D E E F F E C T S

On short term administration, the most common adverse reported with the drug include:
Diarrhoea (1.5%)
Diziness (0.7%)
Pruritis (0.06%)
Skin rash ( 0.4%)
These are generally mild or of moderate intensity, rarely necessitating treatment withdrawal.

P R E S E N TAT I O N & PACK

Toprazol tablet is available in blister pack of 10 x 10’s.

Vast™

An unique ayurvedic cough syrup

D E S C R I P T I O N / M O D E O F A C T I O N
Vast is an ayurvedic cough syrup with unique combination of cough ingredients. Vast abates cough quickly and provides soothing effect reducing throat and bronchial irritation. Vast has a broad spectrum activity which relieves cough of varied aetiology. Vast relieves bronchial congestion and reduces susceptibility to cough by increasing resistance.

C O M P O S I T I O N

Each 5ml of Vast contains extracts equivalent to :

Qty in mg.
Ocimum sanctum (Tulasi) 100
Adhatoda vasika (Vasaka) 50
Sida cordifolia (Bala) 20
Inula racemosa (Pushkaramoola) 50
Glycyrrhiza glabra (Yashtimadhu) 50
Zingiber officinale (Sringavera / Shunti) 15
Piper longum (Pippali) 15
Albizzia lebbeck (Shirisha) 50
Navasara 80


I N D I C AT I O N S

Vast is indicated in cough, allergic bronchitis, tracheitis, bronchiolitis

D O S A G E

Adult – 10 ml tid
Children - 2.5 ml – 5 ml tid

S I D E E F F E C T S
Being an ayuvedic preparation, no untoward side effects are observed

P R E S E N TAT I O N & PACK
Bottle of 100 ml



VITALPHA & VITALPHA - C™

better solution in Osteopenic fragility

D E S C R I P T I O N / M O D E O F A C T I O N
Vitalpha (Alfacalcidol) is an analogue of calciol (cholecalciferol, vitamin D3 ) which is hydroxylated to calcitriol (1,25 dihydroxy cholecalciferol, 1,25-(OH)2 vitamin D3 ), the most potent natural metabolite of calciol. Alfacalcidol is fat soluble and absorbed upto 100%. After absorption, Alfacalcidol is rapidly hydroxylated at the 25 th position, predominantly in the liver. After hydroxylation Alfacalcidol is converted to 1,25 dihydroxy cholecalciferol [1,25 dihydroxy vit. D3 , calcitriol]. By virtue of its high solubility in the lipids, Alfacalcidol is rapidly distributed throughout the body and appear in plasma within 30 minutes. Plasma half-life is 3 hours. 13% gets excreted through urine, 5% through faeces and the balance as other metabolites. Vitalpha – C is a combination of Alfacalcidol with Elemental Calcium recommended in osteoporotic patients with low dietary calcium intake.

C O M P O S I T I O N

Vitalpha 0.25 & 1 contains: Alfacalcidol (1-a hydroxy vitamin D3 ) 0.25 mcg & 1 mcg
Vitalpha – C contains: Alfacalcidol (1-a hydroxy vitamin D3 ) 0.25 mcg + Elemental Calcium 200 mg

I N D I C AT I O N S

Alfacalcidol is indicated for the treatment of diseases caused by disturbances in calcium metabolism as a consequence of reduced endogenous production of 1,25 (OH)2 D3 .
Osteoporosis
Renal osteodystrophy
Neonatal hypocalcaemia
Vitamin D dependent rickets
Rickets in premature infants
Hypocalcaemia in hypoparathyroidism
Osteomalacia due to malabsorption syndrome
Hypocalcaemia & hypomagnesaemia after small bowel resection
Hypocalcaemia and parathyroid bone disease after parathyroidectomy
VITALPHA – C is a fortified vital therapy indicated in Glucocorticoid induced/diabetic/senile/postmenopausal osteoporotic cases.

D O S A G E

The recommended dosage is 0.25 mcg to 2 mcg per day depending on the condition and response.
All indications, except in Osteoporosis
Adults 1 mcg / day
Elderly patients 0.5 mcg / day
Children 20 kg & over 1 mcg / day
(Excepting in renal osteodystrophy)
In renal osteodystrophy 0.5 to 2 mcg / day (0.04 to 0.08 mcg / kg / day)
Children under 20 kg 0.05 mcg / kg / day
Osteoporosis 0.5 mcg / day
VITALPHA – C : One to four capsules per day in single dose depending on the condition and response.
Periodic monitoring of plasma calcium level and dose alteration accordingly is suggested.

S I D E E F F E C T S

Alfacalcidol has a low therapeutic index and possible adverse effects can be hypercalcaemia, hyperphosphataemia or hypermagnesaemia. Alfacalcidol, should not be used in patients with evidence of Vitamin D toxicity or known hyper sensitivity to the effects of Vitamin D or any of its analogues.

P R E S E N TAT I O N & PACK

Vitalpha is available in 0.25 mcg and 1 mcg in soft gelatin capsules in blister strips of 10 X 10s.
Vitalpha-C is available in soft gelatin capsules in blister strips of 10 X 10s .

VITATROL™- PLUS

The Vital Bone Matrix Optimizer

D E S C R I P T I O N / M O D E O F A C T I O N

Vitatrol plus contains Calcitriol, Calcium Carbonate and Zinc Sulphate.
Calcitriol
- Most active form of vitamin D. Calcitriol regulates calcium homoeostasis and helps maintain normal calcium and phosphorus levels in the plasma and bone. . The plasma calcium level is increased by increased absorption of calcium from the gut and by decreasing renal calcium excretion. Independent of the above action calcitriol enhances bone mineralisation
Calcium Carbonate
- Is present in all tissues of the body the major portion is found in the bones. In fact the bones act like calcium reservoir. Dietary deficiency of calcium is thought to play a significant role in the development of osteoporosis.
Zinc
- Bone growth retardation is a common finding in various conditions associated with zinc deficiency. Zinc has been demonstrated to have stimulatory effect on bone formation and mineralisation. Zinc directly activates aminoacyl – t RNA synthesis in osteoblastic cells and improves protein synthesis. It also inhibits osteoclastic bone resorption by inhibiting osteoclast formation from the bone marrow.

C O M P O S I T I O N

Each softgel Capsule contains
Calcitriol - 0.25mcg
Calcium Carbonate - 250mg
Zinc Sulphate - 7.5mg

I N D I C AT I O N S

vPostmenopausal osteoporosis
vSenile osteoporosis
vCorticosteroid induced osteoporosis

D O S A G E

The recommended dosage is one capsule twice daily. Serum Calcium levels are monitored frequently.


CONTRAINDICATIONS

Hypersensitivity to any of the ingredients
Hypocalcaemia


P R E S E N TAT I O N & PACK

Vitatrol Plus is available in soft gelatin capsules in blister strips of 10 X 10’s .



VERPENEM™
An ACE among Antibacterials

D E S C R I P T I O N / M O D E O F A C T I O N

Verpenem belongs to Carbapenems
— Structure -Addition of methyl group in 1-position of the carbapenem moiety
— Cell wall synthesis inhibitor
— Active against- Gram positive ,Gram negative
— Anaerobic
— Sensitive even to organisms producing - Beta- lactamase ,Pencillinase ,MRSA
— Klebsiella pneumoniae,Enterobacter cloacae,Pseudomonas aeruginosa,Acinetobacter baumannii,
Haemophilus influenzae, Bacteroides fragilis.
— ESBL producing pathogens
— Dose (mg)- 500-2000 , Half life - 1h, Protein binding- 2-10%
— Not hydrolysed by DHP-1

C O M P O S I T I O N

Meropenem - 1gm & 500 mg Vials.

I N D I C AT I O N S

— Bacterial meningitis
Ř Bacteriological cure rate – 97%
— Complicated intra abdominal infection- 91%
— Febrile neutropenia.
— Lower respiratory infections
Ř Cystic fibrosis - 98%
Ř Nosocomial pneumonia - 91%
Ř Community acquired pneumonia – near 100%
— Complicated Skin & Soft Tissue injuries- cSSTIs
Ř Surgical wound
Ř Severe diabetic foot infections
Ř Burns
— Septicaemia, septic shock
— Complicated Urinary Tract Infection
— Gynaecological infection

D O S A G E
Dose (mg)- 500-2000


S I D E E F F E C T S
Less renal toxic
seizure rate of 0.08%
GI Adverse effects- low at 1.4%


P R E S E N TAT I O N & PACK
Meropenem – 1 gm & 500 mg Vials with Distilled Water & Tray.



VERIXIME™

Strikes Out All Infections

D E S C R I P T I O N / M O D E O F A C T I O N

Cefixime belongs to third generation Cephalosporins
— Bactericidal antibiotic - Cell wall synthesis inhibitor
— Active against- Gram positive ,Gram negative
— Sensitive even to organisms producing - Beta- lactamase
— Klebsiella pneumoniae,Enterobacter cloacae,Moraxella catarrhalis , Acinetobacter baumannii,
Neisseria gonorrhoeae, Haemophilus influenzae, Bacteroides fragilis.
— ESBL producing pathogens
— Oral absorption 40- 50%,Peak plasma concentration – 2-3micro gram/ml, Half life – 3-4h
— Protein binding- 65%
— Not hydrolysed by DHP-1

C O M P O S I T I O N

Verixime-DT contains Cefixime Dispersable tablet 100 mg
Verixime- 200 contains Cefixime tablet 200 mg


I N D I C AT I O N S

v Gonorrhea
v Otitis media
v Pharngitis
v LRTI- bronchitis
v UTI
v Enteric fever
v Biliary infection

D O S A G E
Adults- 400mg daily as single dose/ in 2 divided doses
Children – 8mg/kg/ day once daily or in 2 divided doses

S I D E E F F E C T S
GI Adverse effects- diarrhea, stool changes
Hypoprothrombinaemia

P R E S E N TAT I O N & PACK
Verixime-DT- 10x10’s blister pack
Verixime- 200- 10x10’s blister pack
Verixime Dry syrup



VERZIT™

The Victorious Verdict Against All Bacteria

D E S C R I P T I O N / M O D E O F A C T I O N

Verzit belongs to Macrolides, Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.
— Bactericidal antibiotic – bacterial protein synthesis inhibitor.
— It combines with 50S ribosome subunits & interferences with translocation.
— Active against- mostly Gram positive and few Gram negative bacteria
— High activity is exerted on respiratory pathogens –
— Mycoplasma, Chlamydia pneumonia,Moraxella catarrhalis
Neisseria gonorrhoeae,H ducreyi, campylobacter, Ch.trachomatis
— Acid stable good oral absorption,marked tissue distribution & intracellular penetration

C O M P O S I T I O N

Verzit - AZITHROMYCIN 100 mg DT, 250 mg & 500 mg Tabs

I N D I C AT I O N S

v Acute bacterial exacerbations of chronic obstructive pulmonary disease
v Acute bacterial sinusitis/Acute otitis media
v Community-acquired pneumonia
v Pharyngitis/Tonsillitis
v Uncomplicated skin and skin structure infections
v Urethritis and cervicitis
v Genital ulcer disease
v Adjuvant therapy in malaria & cholera

D O S A G E

Infections Recommended Dose / Duration of Therapy
Community-aquired pneumonia (mild severity) Pharyngitis/tonsillitis (second line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
Acute bacterial exacerbations of chronic obstructive pulmonary disease (mild to moderate) 500 mg QD x 3 days OR 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
Acute bacterial sinusitis 500 mg QD x 3 days
Genital ulcer disease (chancroid) One single 1 gram dose
Non-gonoccocal urethritis and cervicitis One single 1 gram dose
Gonococcal urethritis and cervicitis One single 2 gram dose


S I D E E F F E C T S
angioedema and cholestatic jaundice
gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain.

P R E S E N TAT I O N & PACK
Verzit-100 DT- 1 x 3’s Alu-Alu pack
Verzit-250-1 x 6’s Alu-Alu pack
Verzit-500-1 x 3’s Alu-Alu pack


VERCLAV™

The Bacterial Claw Against Microbes

D E S C R I P T I O N / M O D E O F A C T I O N
Verclav is a combination of Amoxicillin and clavulanic acid.
Amoxicillin: This drug, penicillinase-susceptible semi-synethetic penicillin, is a close chemical and pharmacological relative of ampicillin. aminopenicillins are bactericidal for both gram-positive and gram-negative bacteria. The meningococci and L. monocytogenes are sensitive to the drug. Most strains of Shigella are now resistant. Most strains of Pseudomonas, Klebsiella, Serratia Acinetobacter, and indolepositive Proteus also are resistant to this group of penicillin. However, concurrent administration of a b-lactamase inhibitor such as clavulanate or sulbactam markedly expands the spectrum of activity of these drugs.
Clavulanic acid has poor intrinsic antimicrobial action, (by itself it cannot kill the bacteria) but it is a ‘suicide’ inhibitor. It combines irreversibly with Beta lactamase enzyme rendering the enzyme inactive. This inactivated enzyme is unable to destroy Beta lactamase antibiotics (penicillins and cephalosporins). Thus a resistant organism becomes susceptible to the action of antibiotics.

C O M P O S I T I O N

Clavulanate Potassium and Amoxycillin Tabs / Inj

Tablets 625 mg / 375 mg & Injection 1.2 g / 600 mg / 300 mg
Dry Syrup – Each 5ml contains Amoxycillin200mg plus Clavulanic acid 28.5mg

I N D I C AT I O N S

v Bacterial meningitis
v Peritonitis
v Post-operative infections
v Genitor-urinary infections
v LRTI- bronchitis
v UTI
v Skin & soft tissue infection
v Enteric fever

D O S A G E
Adults- 250-500 mg every 8hr/ 500-750 mg every 12 hr
Children – 125-250 mg every 8 hr, if less than <40 kg: 20-40 mg/kg/day


S I D E E F F E C T S

GI Adverse effects- diarrhea, Candidiasis, antibiotic-associated colitis
Hypersensitivity reactions
Skin rash, (urticarial and erythematous) sometimes occurs. Rarely erythema multiforme,
Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis and acute generalised exanthematous opustulosis

C O N T R A I N D I C A T I O N S

Penicillin hypersensitivity.
Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics, e.g. Cephalosporins.
A previous history of Clavulanate Potassium and Amoxycillin Injection or Penicillin associated jaundice/hepatic dysfunction


P R E S E N TAT I O N & PACK

Verclav 375 mgTab- 10x6 Alu Alu pack
Verclav 625 mgTab - 10x6 Alu Alu pack
Verclav Dry Syrup
Verclav inj- 300 mg/ 600 mg/ 1.2 gm

Zinfe – SR™

A haematinic with Zinc and Vitamins

D E S C R I P T I O N / M O D E O F A C T I O N
Zinfe – SR is a sustained release haematinic with Zinc, specially formulated for the expectant mother, which ensures maternal and foetal care. Besides combining Iron & Zinc, Zinfe – SR incorporates other complimentary factors for haemopoiesis viz. Vitamin B12, Vitamin B 6, and Folic acid. Zinfe – SR is designed to provide therapeutic supplement in pregnancy anaemia and also in general anaemia arising out of parasitic infestations, blood loss, haemorrhoids etc.

C O M P O S I T I O N

Each sustained release capsule contains :

Ferrous sulphate 150 mg
Zinc sulphate 61.8 mg
Folic acid 1.5 mg
Vitamin B 12 15 mcg
Vitamin B 6 3 mg

I N D I C AT I O N S

Zinfe – SR is indicated in pregnancy anaemia, nutritional anaemia, parasitic anaemia, Zinc deficiency and in post operative cases as a supplement.

D O S A G E

One to two capsule / day during pregnancy related anaemia.
One capsule twice daily during severe anaemic conditions.

S I D E E F F E C T S

Hyper sensitivity to Zinfe – SR is rare. Tetracycline should not be combined with Zinfe – SR. It is advisable to avoid taking Zinfe – SR with hot water and to avoid using in renal failure. Zinc is known to interact with Fluroquinolines and Penicillamine reduces absorption. Adverse effects though rare, are nausea, vomiting and abdominal pain.

P R E S E N TAT I O N & PACK

Strips of 10 X 10’s sustained release capsules in blister pack.










© 2003 Karnataka Antibiotics & Pharmaceuticals Limited. All rights reserved. Developed and Hosted by SIFY Limited.